// ============================================================
// TERRAIN — Indication Data Map
// lib/data/indication-map.ts
//
// Static database of 152 indications with epidemiology data.
// Covers: oncology (42), rare disease (29), neurology (24), immunology (16),
// cardiovascular (13), infectious disease (6), hematology (5), ophthalmology (5),
// pulmonology (4), nephrology (4), metabolic (4).
// Sources: SEER, ACS, WHO GBD, CDC, disease foundations, published literature.
// ============================================================

export interface IndicationData {
  name: string;
  synonyms: string[];
  icd10_codes: string[];
  therapy_area: string;
  us_prevalence: number;         // Number of US patients with condition
  us_incidence: number;          // New cases per year in US
  prevalence_source: string;
  diagnosis_rate: number;        // 0-1: % of prevalent patients who are diagnosed
  treatment_rate: number;        // 0-1: % of diagnosed who receive treatment
  cagr_5yr: number;              // Market CAGR %
  major_competitors: string[];   // Approved/late-stage drugs
  market_growth_driver: string;
  therapy_area_pricing_context: string;
}

export const INDICATION_DATA: IndicationData[] = [

  // ──────────────────────────────────────────
  // ONCOLOGY
  // ──────────────────────────────────────────
  {
    name: 'Non-Small Cell Lung Cancer',
    synonyms: ['NSCLC', 'lung adenocarcinoma', 'lung squamous cell carcinoma', 'lung cancer'],
    icd10_codes: ['C34.10', 'C34.11', 'C34.12', 'C34.30'],
    therapy_area: 'oncology',
    us_prevalence: 235000,
    us_incidence: 236740,
    prevalence_source: 'American Cancer Society 2024; SEER Database',
    diagnosis_rate: 0.85,
    treatment_rate: 0.78,
    cagr_5yr: 9.2,
    major_competitors: [
      'Keytruda (pembrolizumab, MSD)',
      'Opdivo (nivolumab, BMS)',
      'Tagrisso (osimertinib, AstraZeneca)',
      'Alecensa (alectinib, Roche)',
      'Lorbrena (lorlatinib, Pfizer)',
      'Lumakras (sotorasib, Amgen)',
      'Krazati (adagrasib, Mirati)',
    ],
    market_growth_driver: 'Expanding biomarker-selected populations, combination regimens, and earlier-line treatment opportunities',
    therapy_area_pricing_context: 'Oncology premium pricing environment; $150K-$250K annually typical for targeted therapies',
  },

  {
    name: 'Pancreatic Ductal Adenocarcinoma',
    synonyms: ['PDAC', 'pancreatic cancer', 'pancreatic adenocarcinoma'],
    icd10_codes: ['C25.0', 'C25.1', 'C25.2', 'C25.3', 'C25.9'],
    therapy_area: 'oncology',
    us_prevalence: 62000,
    us_incidence: 66440,
    prevalence_source: 'American Cancer Society 2024; National Cancer Database',
    diagnosis_rate: 0.90,        // High because symptomatic presentation
    treatment_rate: 0.75,        // Many patients diagnosed at unresectable stage
    cagr_5yr: 11.5,
    major_competitors: [
      'Gemcitabine (generic)',
      'FOLFIRINOX regimen',
      'Abraxane (nab-paclitaxel)',
      'Olaparib (AstraZeneca, BRCA+ only)',
    ],
    market_growth_driver: 'Massive unmet need, rising incidence, KRAS targeted therapy emerging, ADC combinations',
    therapy_area_pricing_context: 'High unmet need supports premium pricing. First effective targeted therapy could command $200K+ annually',
  },

  {
    name: 'Acute Myeloid Leukemia',
    synonyms: ['AML', 'acute myelogenous leukemia'],
    icd10_codes: ['C92.00', 'C92.01', 'C92.02', 'C92.60', 'C92.40'],
    therapy_area: 'oncology',
    us_prevalence: 35000,
    us_incidence: 20800,
    prevalence_source: 'SEER Database 2024; Leukemia and Lymphoma Society',
    diagnosis_rate: 0.95,
    treatment_rate: 0.85,
    cagr_5yr: 8.8,
    major_competitors: [
      'Venclexta (venetoclax, AbbVie/Roche)',
      'Enasidenib (Bristol Myers Squibb)',
      'Ivosidenib (Servier)',
      'Quizartinib (Daiichi Sankyo)',
      'Gilteritinib (Astellas)',
    ],
    market_growth_driver: 'Molecular subtype targeting expansion, frontline combination opportunities, MRD-driven treatment strategies',
    therapy_area_pricing_context: 'Hematology oncology commands $150K-$300K+ annually; intensity of therapy supports high pricing',
  },

  {
    name: 'Triple Negative Breast Cancer',
    synonyms: ['TNBC', 'triple negative breast cancer', 'breast cancer'],
    icd10_codes: ['C50.01', 'C50.02', 'C50.11', 'C50.12'],
    therapy_area: 'oncology',
    us_prevalence: 42000,
    us_incidence: 43000,
    prevalence_source: 'American Cancer Society 2024; BreastCancer.org Statistics',
    diagnosis_rate: 0.92,
    treatment_rate: 0.88,
    cagr_5yr: 10.1,
    major_competitors: [
      'Keytruda (pembrolizumab, MSD)',
      'Trodelvy (sacituzumab govitecan, Gilead)',
      'Lynparza (olaparib, AstraZeneca/MSD, germline BRCA)',
      'Talzenna (talazoparib, Pfizer, germline BRCA)',
    ],
    market_growth_driver: 'ADC wave, TROP2 targets, immunotherapy combination, BRCA-targeted expansion',
    therapy_area_pricing_context: 'Breast oncology: $100K-$200K annually typical. ADCs command premium.',
  },

  {
    name: 'Colorectal Cancer',
    synonyms: ['CRC', 'colon cancer', 'rectal cancer', 'colorectal adenocarcinoma'],
    icd10_codes: ['C18', 'C19', 'C20', 'C21'],
    therapy_area: 'oncology',
    us_prevalence: 188000,
    us_incidence: 154270,
    prevalence_source: 'American Cancer Society 2024; SEER 5-year survival data',
    diagnosis_rate: 0.87,
    treatment_rate: 0.82,
    cagr_5yr: 7.8,
    major_competitors: [
      'Avastin (bevacizumab, Roche)',
      'Vectibix (panitumumab, Amgen)',
      'Erbitux (cetuximab, Eli Lilly)',
      'Opdivo + Yervoy (BMS, MSI-H)',
      'KRAZATI (adagrasib, KRAS G12C)',
    ],
    market_growth_driver: 'MSI-H immunotherapy expansion, KRAS-targeted therapies, EGFR combinations',
    therapy_area_pricing_context: 'Competitive landscape; targeted agents $80K-$150K annually',
  },

  {
    name: 'Ovarian Cancer',
    synonyms: ['ovarian carcinoma', 'EOC', 'epithelial ovarian cancer', 'ovarian adenocarcinoma'],
    icd10_codes: ['C56.1', 'C56.2', 'C56.9'],
    therapy_area: 'oncology',
    us_prevalence: 72000,
    us_incidence: 19680,
    prevalence_source: 'American Cancer Society 2024; OCRA Foundation',
    diagnosis_rate: 0.82,        // Often late-stage at diagnosis
    treatment_rate: 0.90,
    cagr_5yr: 9.5,
    major_competitors: [
      'Lynparza (olaparib, AstraZeneca/MSD)',
      'Zejula (niraparib, GSK)',
      'Rubraca (rucaparib, Clovis/Pfizer)',
      'Avastin (bevacizumab, Roche)',
    ],
    market_growth_driver: 'PARP inhibitor maintenance expansion, HRD testing, ADC development, VEGF combinations',
    therapy_area_pricing_context: 'PARP inhibitors set $150K+ benchmark; follow-on assets need differentiation for premium pricing',
  },

  {
    name: 'Diffuse Large B-Cell Lymphoma',
    synonyms: ['DLBCL', 'large B-cell lymphoma', 'aggressive NHL', 'diffuse large B cell'],
    icd10_codes: ['C83.30', 'C83.31', 'C83.32', 'C83.33', 'C83.39'],
    therapy_area: 'oncology',
    us_prevalence: 72000,
    us_incidence: 28000,
    prevalence_source: 'SEER Database 2024; Leukemia and Lymphoma Society',
    diagnosis_rate: 0.93,
    treatment_rate: 0.90,
    cagr_5yr: 12.5,
    major_competitors: [
      'Yescarta (axicabtagene ciloleucel, Gilead) — CAR-T',
      'Kymriah (tisagenlecleucel, Novartis) — CAR-T',
      'Breyanzi (lisocabtagene maraleucel, BMS) — CAR-T',
      'Polivy (polatuzumab vedotin, Roche)',
      'Columvi (glofitamab, Roche) — bispecific',
      'Epkinly (epcoritamab, AbbVie/Genmab) — bispecific',
      'R-CHOP (generic rituximab + chemo)',
    ],
    market_growth_driver: 'CAR-T moving to earlier lines, bispecific antibodies expanding access, novel combinations for relapsed/refractory',
    therapy_area_pricing_context: 'CAR-T therapies at $373K-$410K one-time; bispecifics at $150K-$200K annually. Curative intent justifies high pricing.',
  },

  {
    name: 'Follicular Lymphoma',
    synonyms: ['FL', 'follicular NHL', 'indolent lymphoma', 'follicular non-Hodgkin lymphoma'],
    icd10_codes: ['C82.00', 'C82.01', 'C82.02', 'C82.09', 'C82.10'],
    therapy_area: 'oncology',
    us_prevalence: 100000,
    us_incidence: 15000,
    prevalence_source: 'SEER Database 2024; Lymphoma Research Foundation',
    diagnosis_rate: 0.90,
    treatment_rate: 0.75,
    cagr_5yr: 8.2,
    major_competitors: [
      'Gazyva (obinutuzumab, Roche)',
      'Rituxan (rituximab, Roche/Biogen)',
      'Monjuvi (tafasitamab, MorphoSys/Incyte)',
      'Columvi (glofitamab, Roche)',
      'Epkinly (epcoritamab, AbbVie/Genmab)',
      'Tazverik (tazemetostat, Ipsen)',
      'Copiktra (duvelisib, Secura Bio)',
    ],
    market_growth_driver: 'Time-limited regimens, bispecific antibodies, novel combinations replacing chemoimmunotherapy, watch-and-wait conversion',
    therapy_area_pricing_context: 'Indolent disease with long treatment duration; $80K-$150K annually. Biosimilar rituximab creating pricing pressure.',
  },

  {
    name: 'Multiple Myeloma',
    synonyms: ['MM', 'myeloma', 'plasma cell myeloma', 'Kahler disease'],
    icd10_codes: ['C90.00', 'C90.01', 'C90.02'],
    therapy_area: 'oncology',
    us_prevalence: 160000,
    us_incidence: 35730,
    prevalence_source: 'American Cancer Society 2024; SEER Database',
    diagnosis_rate: 0.92,
    treatment_rate: 0.90,
    cagr_5yr: 9.8,
    major_competitors: [
      'Darzalex (daratumumab, Janssen)',
      'Revlimid (lenalidomide, BMS)',
      'Pomalyst (pomalidomide, BMS)',
      'Velcade (bortezomib, Takeda/Janssen)',
      'Kyprolis (carfilzomib, Amgen)',
      'Carvykti (ciltacabtagene autoleucel, Janssen) — BCMA CAR-T',
      'Abecma (idecabtagene vicleucel, BMS) — BCMA CAR-T',
      'Tecvayli (teclistamab, Janssen) — bispecific',
      'Talvey (talquetamab, Janssen) — bispecific',
    ],
    market_growth_driver: 'BCMA-targeted therapies, bispecific expansion to earlier lines, quadruplet frontline regimens, MRD-driven treatment decisions',
    therapy_area_pricing_context: 'Premium hematology-oncology pricing; $150K-$400K annually. CAR-T at $400K+ one-time.',
  },

  {
    name: 'Renal Cell Carcinoma',
    synonyms: ['RCC', 'kidney cancer', 'renal cancer', 'clear cell RCC', 'ccRCC'],
    icd10_codes: ['C64.1', 'C64.2', 'C64.9'],
    therapy_area: 'oncology',
    us_prevalence: 175000,
    us_incidence: 81800,
    prevalence_source: 'American Cancer Society 2024; SEER Database; Kidney Cancer Association',
    diagnosis_rate: 0.88,
    treatment_rate: 0.80,
    cagr_5yr: 8.5,
    major_competitors: [
      'Keytruda (pembrolizumab, MSD)',
      'Opdivo + Yervoy (nivolumab + ipilimumab, BMS)',
      'Cabometyx (cabozantinib, Exelixis)',
      'Lenvima + Keytruda (lenvatinib + pembrolizumab, Eisai/MSD)',
      'Inlyta (axitinib, Pfizer)',
      'Welireg (belzutifan, MSD) — HIF-2a inhibitor',
    ],
    market_growth_driver: 'IO+TKI combinations in 1L, HIF-2a inhibitor expansion, adjuvant immunotherapy, biomarker-selected populations',
    therapy_area_pricing_context: 'IO+TKI combos at $200K-$350K annually combined; single-agent TKIs $150K+.',
  },

  {
    name: 'Hepatocellular Carcinoma',
    synonyms: ['HCC', 'liver cancer', 'hepatocellular cancer', 'primary liver cancer'],
    icd10_codes: ['C22.0', 'C22.9'],
    therapy_area: 'oncology',
    us_prevalence: 65000,
    us_incidence: 41210,
    prevalence_source: 'American Cancer Society 2024; SEER Database',
    diagnosis_rate: 0.80,
    treatment_rate: 0.72,
    cagr_5yr: 10.8,
    major_competitors: [
      'Tecentriq + Avastin (atezolizumab + bevacizumab, Roche)',
      'Imfinzi + Imjudo (durvalumab + tremelimumab, AstraZeneca)',
      'Lenvima (lenvatinib, Eisai)',
      'Nexavar (sorafenib, Bayer)',
      'Cabometyx (cabozantinib, Exelixis)',
    ],
    market_growth_driver: 'IO combinations expanding frontline dominance, adjuvant/neoadjuvant immunotherapy, novel IO+TKI combinations',
    therapy_area_pricing_context: 'IO+anti-VEGF combos at $200K+ annually. High unmet need in second-line and beyond supports premium pricing.',
  },

  {
    name: 'Gastric/Gastroesophageal Junction Cancer',
    synonyms: ['gastric cancer', 'GEJ cancer', 'stomach cancer', 'gastroesophageal junction adenocarcinoma'],
    icd10_codes: ['C16.0', 'C16.1', 'C16.2', 'C16.3', 'C16.9'],
    therapy_area: 'oncology',
    us_prevalence: 45000,
    us_incidence: 26890,
    prevalence_source: 'American Cancer Society 2024; SEER Database',
    diagnosis_rate: 0.85,
    treatment_rate: 0.78,
    cagr_5yr: 9.0,
    major_competitors: [
      'Keytruda (pembrolizumab, MSD)',
      'Opdivo (nivolumab, BMS)',
      'Enhertu (trastuzumab deruxtecan, Daiichi Sankyo/AstraZeneca) — HER2+',
      'Herceptin (trastuzumab, Roche) — HER2+',
      'Cyramza (ramucirumab, Eli Lilly)',
      'Zolbetuximab (Astellas) — CLDN18.2+',
    ],
    market_growth_driver: 'Claudin 18.2 targeting, ADC expansion, immunotherapy combinations, biomarker-stratified approaches',
    therapy_area_pricing_context: 'Oncology standard pricing; IO agents $150K+ annually. Novel targets like CLDN18.2 can command premium.',
  },

  {
    name: 'Urothelial Carcinoma',
    synonyms: ['bladder cancer', 'urothelial cancer', 'transitional cell carcinoma', 'bladder urothelial carcinoma'],
    icd10_codes: ['C67.0', 'C67.1', 'C67.2', 'C67.9'],
    therapy_area: 'oncology',
    us_prevalence: 250000,
    us_incidence: 83190,
    prevalence_source: 'American Cancer Society 2024; SEER Database',
    diagnosis_rate: 0.88,
    treatment_rate: 0.80,
    cagr_5yr: 11.2,
    major_competitors: [
      'Keytruda (pembrolizumab, MSD)',
      'Opdivo (nivolumab, BMS)',
      'Padcev (enfortumab vedotin, Seagen/Astellas) — ADC',
      'Balversa (erdafitinib, Janssen) — FGFR inhibitor',
      'Tecentriq (atezolizumab, Roche)',
    ],
    market_growth_driver: 'EV-302 paradigm shift (Padcev+Keytruda in 1L), ADC class expansion, FGFR-targeted therapy, adjuvant IO post-cystectomy',
    therapy_area_pricing_context: 'ADC+IO combinations at $250K-$400K annually combined. Significant clinical advance supports premium.',
  },

  {
    name: 'Melanoma',
    synonyms: ['cutaneous melanoma', 'malignant melanoma', 'skin melanoma', 'metastatic melanoma'],
    icd10_codes: ['C43.0', 'C43.1', 'C43.2', 'C43.3', 'C43.4', 'C43.9'],
    therapy_area: 'oncology',
    us_prevalence: 200000,
    us_incidence: 100640,
    prevalence_source: 'American Cancer Society 2024; SEER Database; Melanoma Research Foundation',
    diagnosis_rate: 0.92,
    treatment_rate: 0.85,
    cagr_5yr: 7.5,
    major_competitors: [
      'Keytruda (pembrolizumab, MSD)',
      'Opdivo (nivolumab, BMS)',
      'Opdivo + Yervoy (nivolumab + ipilimumab, BMS)',
      'Opdualag (nivolumab + relatlimab, BMS) — anti-LAG-3',
      'Tafinlar + Mekinist (dabrafenib + trametinib, Novartis) — BRAF V600',
      'Braftovi + Mektovi (encorafenib + binimetinib, Pfizer)',
      'Libtayo (cemiplimab, Regeneron/Sanofi)',
    ],
    market_growth_driver: 'Adjuvant/neoadjuvant IO expansion, novel IO combinations (LAG-3, TIGIT), BRAF-mutant combinations, uveal melanoma unmet need',
    therapy_area_pricing_context: 'IO therapies at $150K-$200K annually; adjuvant duration limits total cost. Combinations push toward $300K+.',
  },

  {
    name: 'Metastatic Castration-Resistant Prostate Cancer',
    synonyms: ['mCRPC', 'prostate cancer', 'castration-resistant prostate cancer', 'CRPC', 'advanced prostate cancer'],
    icd10_codes: ['C61'],
    therapy_area: 'oncology',
    us_prevalence: 160000,
    us_incidence: 288300,
    prevalence_source: 'American Cancer Society 2024; SEER Database; Prostate Cancer Foundation',
    diagnosis_rate: 0.90,
    treatment_rate: 0.82,
    cagr_5yr: 8.8,
    major_competitors: [
      'Xtandi (enzalutamide, Pfizer/Astellas)',
      'Zytiga (abiraterone, Janssen)',
      'Nubeqa (darolutamide, Bayer)',
      'Erleada (apalutamide, Janssen)',
      'Pluvicto (177Lu-PSMA-617, Novartis) — radioligand therapy',
      'Lynparza (olaparib, AstraZeneca) — HRR-mutated',
      'Keytruda (pembrolizumab, MSD) — MSI-H',
    ],
    market_growth_driver: 'PSMA-targeted radioligand therapy expansion, PARP inhibitors for HRR-mutated, triplet combinations in mCSPC, earlier line intensification',
    therapy_area_pricing_context: 'AR-pathway inhibitors $100K-$150K annually; radioligand therapy ~$100K per treatment course.',
  },

  {
    name: 'Cervical Cancer',
    synonyms: ['cervical carcinoma', 'cervical squamous cell carcinoma', 'cervical adenocarcinoma'],
    icd10_codes: ['C53.0', 'C53.1', 'C53.8', 'C53.9'],
    therapy_area: 'oncology',
    us_prevalence: 55000,
    us_incidence: 13820,
    prevalence_source: 'American Cancer Society 2024; SEER Database',
    diagnosis_rate: 0.88,
    treatment_rate: 0.85,
    cagr_5yr: 10.5,
    major_competitors: [
      'Keytruda (pembrolizumab, MSD)',
      'Avastin (bevacizumab, Roche)',
      'Tivdak (tisotumab vedotin, Seagen/Genmab) — ADC',
      'Cisplatin/Paclitaxel (generic)',
    ],
    market_growth_driver: 'ADC expansion, IO combinations, tissue factor targeting, rising incidence in younger populations globally',
    therapy_area_pricing_context: 'Oncology standard pricing; ADCs at $150K-$200K annually. Global health disparity creates unique market dynamics.',
  },

  {
    name: 'Endometrial Cancer',
    synonyms: ['endometrial carcinoma', 'uterine cancer', 'uterine corpus cancer', 'endometrial adenocarcinoma'],
    icd10_codes: ['C54.1', 'C54.9', 'C55'],
    therapy_area: 'oncology',
    us_prevalence: 210000,
    us_incidence: 66200,
    prevalence_source: 'American Cancer Society 2024; SEER Database',
    diagnosis_rate: 0.90,
    treatment_rate: 0.82,
    cagr_5yr: 9.8,
    major_competitors: [
      'Keytruda + Lenvima (pembrolizumab + lenvatinib, MSD/Eisai)',
      'Jemperli (dostarlimab, GSK) — dMMR/MSI-H',
      'Keytruda (pembrolizumab, MSD) — dMMR/MSI-H',
      'Carboplatin/Paclitaxel (generic)',
    ],
    market_growth_driver: 'IO+TKI combinations, biomarker-driven therapy (dMMR, HER2, p53), ADC development, rising incidence linked to obesity',
    therapy_area_pricing_context: 'IO+TKI combos at $200K-$300K annually combined. Biomarker-selected populations support targeted pricing.',
  },

  {
    name: 'Thyroid Cancer',
    synonyms: ['thyroid carcinoma', 'differentiated thyroid cancer', 'DTC', 'papillary thyroid cancer', 'medullary thyroid cancer', 'MTC'],
    icd10_codes: ['C73'],
    therapy_area: 'oncology',
    us_prevalence: 880000,
    us_incidence: 44020,
    prevalence_source: 'American Cancer Society 2024; SEER Database; American Thyroid Association',
    diagnosis_rate: 0.90,
    treatment_rate: 0.78,
    cagr_5yr: 8.0,
    major_competitors: [
      'Lenvima (lenvatinib, Eisai)',
      'Nexavar (sorafenib, Bayer)',
      'Cabometyx (cabozantinib, Exelixis) — MTC',
      'Caprelsa (vandetanib, Sanofi) — MTC',
      'Gavreto (pralsetinib, Blueprint/Roche) — RET-mutant',
      'Retevmo (selpercatinib, Eli Lilly) — RET-mutant',
    ],
    market_growth_driver: 'RET-targeted therapies for RET-altered DTC and MTC, BRAF/MEK combinations, radioiodine-refractory DTC unmet need',
    therapy_area_pricing_context: 'Targeted therapies $150K-$200K annually; large prevalent pool but most cured by surgery/RAI.',
  },

  {
    name: 'Head and Neck Squamous Cell Carcinoma',
    synonyms: ['HNSCC', 'head and neck cancer', 'oropharyngeal cancer', 'oral cavity cancer', 'laryngeal cancer'],
    icd10_codes: ['C01', 'C02', 'C03', 'C04', 'C05', 'C06', 'C09', 'C10', 'C12', 'C13', 'C14', 'C32'],
    therapy_area: 'oncology',
    us_prevalence: 120000,
    us_incidence: 66920,
    prevalence_source: 'American Cancer Society 2024; SEER Database',
    diagnosis_rate: 0.85,
    treatment_rate: 0.80,
    cagr_5yr: 8.5,
    major_competitors: [
      'Keytruda (pembrolizumab, MSD)',
      'Opdivo (nivolumab, BMS)',
      'Erbitux (cetuximab, Eli Lilly)',
      'Cisplatin/5-FU (generic)',
    ],
    market_growth_driver: 'IO expansion to earlier stages, HPV-positive vs HPV-negative stratification, de-escalation in favorable prognosis, novel combinations',
    therapy_area_pricing_context: 'IO standard pricing $150K+ annually; HPV-stratified approaches may enable precision pricing.',
  },

  {
    name: 'Glioblastoma',
    synonyms: ['GBM', 'glioblastoma multiforme', 'grade IV glioma', 'high-grade glioma', 'malignant glioma'],
    icd10_codes: ['C71.0', 'C71.1', 'C71.2', 'C71.3', 'C71.4', 'C71.9'],
    therapy_area: 'oncology',
    us_prevalence: 14000,
    us_incidence: 13000,
    prevalence_source: 'CBTRUS 2024; National Brain Tumor Society; SEER Database',
    diagnosis_rate: 0.95,
    treatment_rate: 0.85,
    cagr_5yr: 12.0,
    major_competitors: [
      'Temozolomide (generic)',
      'Avastin (bevacizumab, Roche)',
      'Optune (TTFields, Novocure) — device',
      'Lomustine (generic)',
    ],
    market_growth_driver: 'Massive unmet need (median OS ~15 months), novel IO approaches, targeted therapies for molecular subtypes, mRNA vaccines, BBB-penetrant agents',
    therapy_area_pricing_context: 'Extreme unmet need; novel effective therapies could command $200K+ annually. Optune at $21K/month sets premium device precedent.',
  },

  {
    name: 'Mesothelioma',
    synonyms: ['malignant mesothelioma', 'pleural mesothelioma', 'peritoneal mesothelioma', 'MPM'],
    icd10_codes: ['C45.0', 'C45.1', 'C45.2', 'C45.9'],
    therapy_area: 'oncology',
    us_prevalence: 8000,
    us_incidence: 3000,
    prevalence_source: 'American Cancer Society 2024; SEER Database; Mesothelioma Applied Research Foundation',
    diagnosis_rate: 0.90,
    treatment_rate: 0.82,
    cagr_5yr: 9.5,
    major_competitors: [
      'Opdivo + Yervoy (nivolumab + ipilimumab, BMS)',
      'Cisplatin + Pemetrexed (generic)',
      'Avastin (bevacizumab, Roche)',
    ],
    market_growth_driver: 'IO combination expansion, novel targets (mesothelin, BAP1), ADC development, small patient population supports orphan pricing',
    therapy_area_pricing_context: 'Rare cancer with orphan drug potential; $150K-$250K annually. IO doublet at $250K+ combined.',
  },

  {
    name: 'Small Cell Lung Cancer',
    synonyms: ['SCLC', 'small cell carcinoma of lung', 'oat cell carcinoma', 'small cell lung carcinoma'],
    icd10_codes: ['C34.10', 'C34.11', 'C34.12', 'C34.90'],
    therapy_area: 'oncology',
    us_prevalence: 35000,
    us_incidence: 35000,
    prevalence_source: 'American Cancer Society 2024; SEER Database',
    diagnosis_rate: 0.92,
    treatment_rate: 0.85,
    cagr_5yr: 11.0,
    major_competitors: [
      'Tecentriq (atezolizumab, Roche)',
      'Imfinzi (durvalumab, AstraZeneca)',
      'Etoposide + Cisplatin/Carboplatin (generic)',
      'Zepzelca (lurbinectedin, Jazz Pharma)',
      'Hycamtin (topotecan, Novartis)',
    ],
    market_growth_driver: 'DLL3-targeted therapies (bispecifics, ADCs), novel IO combinations, biomarker-selected subpopulations, limited efficacy of current options drives innovation',
    therapy_area_pricing_context: 'High unmet need despite IO; novel agents could command $150K-$200K annually. Short treatment duration limits revenue per patient.',
  },

  {
    name: 'Merkel Cell Carcinoma',
    synonyms: ['MCC', 'Merkel cell cancer', 'neuroendocrine carcinoma of skin', 'cutaneous neuroendocrine carcinoma'],
    icd10_codes: ['C44.0', 'C44.1', 'C44.9', 'C4A.0'],
    therapy_area: 'oncology',
    us_prevalence: 5000,
    us_incidence: 3000,
    prevalence_source: 'SEER Database 2024; Journal of the American Academy of Dermatology',
    diagnosis_rate: 0.88,
    treatment_rate: 0.85,
    cagr_5yr: 10.0,
    major_competitors: [
      'Bavencio (avelumab, Merck KGaA/Pfizer)',
      'Keytruda (pembrolizumab, MSD)',
      'Opdivo (nivolumab, BMS)',
    ],
    market_growth_driver: 'Ultra-rare cancer with orphan pricing, IO expansion, combination approaches, limited pipeline creates high barrier to entry',
    therapy_area_pricing_context: 'Ultra-rare; orphan drug pricing at $150K-$200K annually. Bavencio set benchmark.',
  },

  {
    name: 'Cholangiocarcinoma',
    synonyms: ['CCA', 'bile duct cancer', 'intrahepatic cholangiocarcinoma', 'iCCA', 'biliary tract cancer'],
    icd10_codes: ['C22.1', 'C24.0', 'C24.8', 'C24.9'],
    therapy_area: 'oncology',
    us_prevalence: 18000,
    us_incidence: 12000,
    prevalence_source: 'American Cancer Society 2024; SEER Database; Cholangiocarcinoma Foundation',
    diagnosis_rate: 0.85,
    treatment_rate: 0.78,
    cagr_5yr: 13.5,
    major_competitors: [
      'Imfinzi + Gemcitabine/Cisplatin (durvalumab, AstraZeneca)',
      'Keytruda (pembrolizumab, MSD) — MSI-H/dMMR',
      'Pemazyre (pemigatinib, Incyte) — FGFR2+',
      'Truseltiq (futibatinib, Taiho) — FGFR2+',
      'Tibsovo (ivosidenib, Servier) — IDH1-mutant',
    ],
    market_growth_driver: 'FGFR2-targeted therapy expansion, IDH-targeted agents, IO+chemo frontline, rising incidence, molecular profiling adoption',
    therapy_area_pricing_context: 'Rare cancer; targeted agents at $150K-$200K annually. Molecular profiling enabling precision pricing.',
  },

  {
    name: 'Adrenocortical Carcinoma',
    synonyms: ['ACC', 'adrenal cortical carcinoma', 'adrenal cancer', 'adrenal cortex cancer'],
    icd10_codes: ['C74.0', 'C74.9'],
    therapy_area: 'oncology',
    us_prevalence: 3000,
    us_incidence: 600,
    prevalence_source: 'SEER Database 2024; National Cancer Institute Rare Cancers Program',
    diagnosis_rate: 0.85,
    treatment_rate: 0.80,
    cagr_5yr: 8.0,
    major_competitors: [
      'Mitotane (generic)',
      'Etoposide/Doxorubicin/Cisplatin (generic)',
      'Keytruda (pembrolizumab, MSD) — investigational',
    ],
    market_growth_driver: 'Extreme unmet need, limited treatment options, orphan drug opportunity, molecular subtyping may enable targeted therapies',
    therapy_area_pricing_context: 'Ultra-rare; orphan drug pricing potential. Effective novel therapy could command $200K+ annually.',
  },

  {
    name: 'Mantle Cell Lymphoma',
    synonyms: ['MCL', 'mantle cell NHL', 'mantle cell non-Hodgkin lymphoma'],
    icd10_codes: ['C83.10', 'C83.11', 'C83.12', 'C83.19'],
    therapy_area: 'oncology',
    us_prevalence: 20000,
    us_incidence: 5000,
    prevalence_source: 'SEER Database 2024; Leukemia and Lymphoma Society',
    diagnosis_rate: 0.92,
    treatment_rate: 0.88,
    cagr_5yr: 10.5,
    major_competitors: [
      'Imbruvica (ibrutinib, Janssen/AbbVie)',
      'Calquence (acalabrutinib, AstraZeneca)',
      'Brukinsa (zanubrutinib, BeiGene)',
      'Tecartus (brexucabtagene autoleucel, Gilead) — CAR-T',
      'Velcade (bortezomib, Takeda)',
    ],
    market_growth_driver: 'BTK inhibitor sequencing, non-covalent BTK inhibitors, CAR-T in earlier lines, combination strategies for high-risk disease',
    therapy_area_pricing_context: 'BTK inhibitors at $150K-$180K annually; CAR-T at $373K one-time. Rare lymphoma supports premium.',
  },

  {
    name: 'Chronic Lymphocytic Leukemia',
    synonyms: ['CLL', 'SLL', 'CLL/SLL', 'chronic lymphocytic leukemia', 'small lymphocytic lymphoma'],
    icd10_codes: ['C91.10', 'C91.11', 'C91.12'],
    therapy_area: 'oncology',
    us_prevalence: 210000,
    us_incidence: 20160,
    prevalence_source: 'SEER Database 2024; Leukemia and Lymphoma Society',
    diagnosis_rate: 0.90,
    treatment_rate: 0.65,
    cagr_5yr: 7.0,
    major_competitors: [
      'Imbruvica (ibrutinib, Janssen/AbbVie)',
      'Calquence (acalabrutinib, AstraZeneca)',
      'Brukinsa (zanubrutinib, BeiGene)',
      'Venclexta (venetoclax, AbbVie/Roche)',
      'Gazyva (obinutuzumab, Roche)',
    ],
    market_growth_driver: 'Fixed-duration venetoclax-based combinations, BTK inhibitor competition, time-limited regimens replacing continuous therapy, MRD-guided approaches',
    therapy_area_pricing_context: 'BTK inhibitors $150K-$180K annually; fixed-duration regimens creating cost-effectiveness pressure. Large prevalent pool.',
  },

  {
    name: "Waldenstrom's Macroglobulinemia",
    synonyms: ['WM', 'Waldenstrom macroglobulinemia', 'lymphoplasmacytic lymphoma', 'LPL'],
    icd10_codes: ['C88.0'],
    therapy_area: 'oncology',
    us_prevalence: 20000,
    us_incidence: 1500,
    prevalence_source: 'SEER Database 2024; International Waldenstrom Macroglobulinemia Foundation',
    diagnosis_rate: 0.88,
    treatment_rate: 0.70,
    cagr_5yr: 7.5,
    major_competitors: [
      'Imbruvica (ibrutinib, Janssen/AbbVie)',
      'Brukinsa (zanubrutinib, BeiGene)',
      'Rituximab (generic)',
      'Bendamustine (generic)',
    ],
    market_growth_driver: 'BTK inhibitor class competition, MYD88/CXCR4 mutation-directed therapy, novel combinations for refractory disease',
    therapy_area_pricing_context: 'Rare hematologic malignancy; BTK inhibitors at $150K-$180K annually. Orphan pricing context.',
  },

  {
    name: 'Myelodysplastic Syndromes',
    synonyms: ['MDS', 'myelodysplasia', 'preleukemia', 'myelodysplastic syndrome'],
    icd10_codes: ['D46.0', 'D46.1', 'D46.2', 'D46.4', 'D46.9'],
    therapy_area: 'oncology',
    us_prevalence: 60000,
    us_incidence: 20000,
    prevalence_source: 'SEER Database 2024; MDS Foundation',
    diagnosis_rate: 0.80,
    treatment_rate: 0.72,
    cagr_5yr: 9.5,
    major_competitors: [
      'Vidaza (azacitidine, BMS)',
      'Dacogen (decitabine, Otsuka)',
      'Reblozyl (luspatercept, BMS) — anemia',
      'Revlimid (lenalidomide, BMS) — del(5q)',
      'Inqovi (decitabine/cedazuridine, Taiho/Astex)',
    ],
    market_growth_driver: 'Novel combinations with HMA backbone, TP53-targeted agents, splicing modulators, higher-risk MDS unmet need, transplant conditioning',
    therapy_area_pricing_context: 'HMAs at $50K-$80K annually; novel agents targeting specific mutations at $100K-$200K.',
  },

  {
    name: 'Myelofibrosis',
    synonyms: ['MF', 'primary myelofibrosis', 'PMF', 'myeloproliferative neoplasm', 'MPN myelofibrosis'],
    icd10_codes: ['D47.4', 'D75.81'],
    therapy_area: 'oncology',
    us_prevalence: 20000,
    us_incidence: 3000,
    prevalence_source: 'MPN Research Foundation 2024; SEER Database',
    diagnosis_rate: 0.82,
    treatment_rate: 0.75,
    cagr_5yr: 10.0,
    major_competitors: [
      'Jakafi (ruxolitinib, Incyte)',
      'Inrebic (fedratinib, BMS)',
      'Vonjo (pacritinib, CTI BioPharma)',
      'Ojjaara (momelotinib, GSK)',
    ],
    market_growth_driver: 'Combination JAK inhibitor approaches, novel targets beyond JAK2, disease modification, BETi combinations, transplant alternatives',
    therapy_area_pricing_context: 'JAK inhibitors at $150K-$180K annually; rare disease pricing with orphan exclusivity.',
  },

  {
    name: 'Polycythemia Vera',
    synonyms: ['PV', 'polycythemia vera', 'primary polycythemia', 'MPN PV'],
    icd10_codes: ['D45'],
    therapy_area: 'oncology',
    us_prevalence: 150000,
    us_incidence: 8000,
    prevalence_source: 'MPN Research Foundation 2024; Blood journal epidemiology studies',
    diagnosis_rate: 0.78,
    treatment_rate: 0.70,
    cagr_5yr: 8.0,
    major_competitors: [
      'Jakafi (ruxolitinib, Incyte)',
      'Besremi (ropeginterferon alfa-2b, PharmaEssentia)',
      'Hydroxyurea (generic)',
      'Aspirin (generic)',
    ],
    market_growth_driver: 'Interferon approaches for early disease, JAK inhibitor expansion, hepcidin mimetics for iron overload, thrombosis prevention',
    therapy_area_pricing_context: 'Besremi at ~$300K annually; Jakafi $150K+. Many patients managed with generic hydroxyurea creating payer segmentation.',
  },

  {
    name: 'Neuroblastoma',
    synonyms: ['NB', 'neuroblastoma', 'high-risk neuroblastoma', 'pediatric neuroblastoma'],
    icd10_codes: ['C74.90', 'C74.91'],
    therapy_area: 'oncology',
    us_prevalence: 6000,
    us_incidence: 800,
    prevalence_source: 'American Cancer Society 2024; SEER Database; COG (Children\'s Oncology Group)',
    diagnosis_rate: 0.95,
    treatment_rate: 0.92,
    cagr_5yr: 12.0,
    major_competitors: [
      'Unituxin (dinutuximab, United Therapeutics) — anti-GD2',
      'DFMO (eflornithine, US WorldMeds) — maintenance',
      'Isotretinoin (generic) — maintenance',
      'Cyclophosphamide/Topotecan (generic)',
    ],
    market_growth_driver: 'Anti-GD2 antibody combinations, ALK inhibitors, CAR-T for relapsed disease, MYCN-targeted approaches, pediatric rare disease pricing',
    therapy_area_pricing_context: 'Pediatric rare cancer; orphan pricing at $200K+ annually. High societal willingness to pay for pediatric oncology.',
  },

  {
    name: 'Ewing Sarcoma',
    synonyms: ['Ewing sarcoma', 'PNET', 'primitive neuroectodermal tumor', 'Ewing family of tumors'],
    icd10_codes: ['C40.0', 'C40.1', 'C40.2', 'C41.9'],
    therapy_area: 'oncology',
    us_prevalence: 3000,
    us_incidence: 400,
    prevalence_source: 'SEER Database 2024; National Cancer Institute Rare Cancers',
    diagnosis_rate: 0.92,
    treatment_rate: 0.90,
    cagr_5yr: 8.5,
    major_competitors: [
      'VDC/IE regimen (vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide)',
      'Temozolomide + Irinotecan (generic)',
      'Lurbinectedin (Jazz Pharma) — investigational',
    ],
    market_growth_driver: 'EWS-FLI1 fusion targeting, immunotherapy approaches, CAR-T targeting EWS antigens, extreme unmet need in relapsed disease',
    therapy_area_pricing_context: 'Ultra-rare pediatric cancer; orphan drug designation available. Novel effective therapies could command $300K+ annually.',
  },

  {
    name: 'Osteosarcoma',
    synonyms: ['OS', 'osteosarcoma', 'osteogenic sarcoma', 'bone cancer'],
    icd10_codes: ['C40.0', 'C40.1', 'C40.2', 'C40.3', 'C41.9'],
    therapy_area: 'oncology',
    us_prevalence: 8000,
    us_incidence: 1000,
    prevalence_source: 'SEER Database 2024; American Cancer Society; Sarcoma Foundation of America',
    diagnosis_rate: 0.90,
    treatment_rate: 0.88,
    cagr_5yr: 7.5,
    major_competitors: [
      'MAP regimen (methotrexate/doxorubicin/cisplatin)',
      'Mifamurtide (not approved in US)',
      'Ifosfamide/Etoposide (generic)',
    ],
    market_growth_driver: 'Extreme unmet need (no new approvals in 40+ years), immunotherapy approaches, GD2 targeting, HER2 targeting, multi-kinase inhibitors',
    therapy_area_pricing_context: 'Ultra-rare; standard of care unchanged for decades. First novel effective therapy could command orphan premium pricing.',
  },

  {
    name: 'Soft Tissue Sarcoma',
    synonyms: ['STS', 'soft tissue sarcoma', 'leiomyosarcoma', 'liposarcoma', 'synovial sarcoma', 'undifferentiated pleomorphic sarcoma'],
    icd10_codes: ['C49.0', 'C49.1', 'C49.2', 'C49.3', 'C49.4', 'C49.9'],
    therapy_area: 'oncology',
    us_prevalence: 50000,
    us_incidence: 13400,
    prevalence_source: 'American Cancer Society 2024; SEER Database; Sarcoma Foundation of America',
    diagnosis_rate: 0.85,
    treatment_rate: 0.80,
    cagr_5yr: 9.0,
    major_competitors: [
      'Doxorubicin (generic)',
      'Votrient (pazopanib, Novartis)',
      'Yondelis (trabectedin, Janssen)',
      'Halaven (eribulin, Eisai) — liposarcoma',
      'Kimmtrak (tebentafusp, Immunocore) — uveal melanoma only',
    ],
    market_growth_driver: 'Subtype-specific targeting, novel immunotherapy approaches, engineered T-cell therapies (afamitresgene autoleucel for synovial sarcoma), ADC development',
    therapy_area_pricing_context: 'Heterogeneous rare cancers; subtype-specific agents at $100K-$200K annually. Orphan designation common.',
  },

  {
    name: 'Esophageal Cancer',
    synonyms: ['esophageal carcinoma', 'esophageal adenocarcinoma', 'esophageal squamous cell carcinoma', 'ESCC'],
    icd10_codes: ['C15.3', 'C15.4', 'C15.5', 'C15.8', 'C15.9'],
    therapy_area: 'oncology',
    us_prevalence: 30000,
    us_incidence: 22370,
    prevalence_source: 'American Cancer Society 2024; SEER Database',
    diagnosis_rate: 0.88,
    treatment_rate: 0.78,
    cagr_5yr: 9.5,
    major_competitors: [
      'Keytruda (pembrolizumab, MSD)',
      'Opdivo (nivolumab, BMS)',
      'Opdivo + Yervoy (BMS)',
      'Enhertu (trastuzumab deruxtecan, Daiichi Sankyo) — HER2+',
      '5-FU/Cisplatin (generic)',
    ],
    market_growth_driver: 'IO expansion in 1L, HER2-targeted ADCs, FGFR targeting, perioperative immunotherapy, biomarker-driven strategies',
    therapy_area_pricing_context: 'IO agents at $150K+ annually; ADCs at $150K-$200K. Short survival limits total cost per patient.',
  },

  {
    name: 'Hodgkin Lymphoma',
    synonyms: ['HL', 'Hodgkin lymphoma', "Hodgkin's disease", "Hodgkin's lymphoma", 'classical Hodgkin lymphoma', 'cHL'],
    icd10_codes: ['C81.0', 'C81.1', 'C81.2', 'C81.3', 'C81.4', 'C81.9'],
    therapy_area: 'oncology',
    us_prevalence: 45000,
    us_incidence: 8830,
    prevalence_source: 'American Cancer Society 2024; SEER Database; Leukemia and Lymphoma Society',
    diagnosis_rate: 0.95,
    treatment_rate: 0.92,
    cagr_5yr: 7.0,
    major_competitors: [
      'Adcetris (brentuximab vedotin, Seagen/Takeda) — ADC',
      'Keytruda (pembrolizumab, MSD)',
      'Opdivo (nivolumab, BMS)',
      'ABVD regimen (generic)',
      'BV-AVD frontline regimen',
    ],
    market_growth_driver: 'Frontline brentuximab-based regimens, IO in relapsed/refractory, de-escalation in favorable prognosis, CAR-T for multiply relapsed',
    therapy_area_pricing_context: 'ADC at $180K+ annually; IO at $150K+. High cure rates limit total treatment duration. Curative intent supports premium pricing.',
  },

  {
    name: 'Chronic Myeloid Leukemia',
    synonyms: ['CML', 'chronic myelogenous leukemia', 'chronic myeloid leukemia', 'Ph+ CML', 'BCR-ABL+ CML'],
    icd10_codes: ['C92.10', 'C92.11', 'C92.12'],
    therapy_area: 'oncology',
    us_prevalence: 70000,
    us_incidence: 9000,
    prevalence_source: 'SEER Database 2024; Leukemia and Lymphoma Society',
    diagnosis_rate: 0.95,
    treatment_rate: 0.92,
    cagr_5yr: 4.5,
    major_competitors: [
      'Gleevec (imatinib, Novartis) — now generic',
      'Sprycel (dasatinib, BMS)',
      'Tasigna (nilotinib, Novartis)',
      'Bosulif (bosutinib, Pfizer)',
      'Iclusig (ponatinib, Takeda) — T315I mutation',
      'Scemblix (asciminib, Novartis) — STAMP inhibitor',
    ],
    market_growth_driver: 'Treatment-free remission strategies, STAMP inhibitor class, generic imatinib pressure driving innovation in 2L+, T315I-targeted therapy',
    therapy_area_pricing_context: 'Generic imatinib at $3K-$8K annually; branded TKIs at $100K-$180K. Asciminib $175K+ for novel mechanism. Chronic lifelong therapy.',
  },

  {
    name: 'HER2-Positive Breast Cancer',
    synonyms: ['HER2+ breast cancer', 'HER2-positive BC', 'ERBB2+ breast cancer', 'HER2-amplified breast cancer'],
    icd10_codes: ['C50.01', 'C50.11', 'C50.21', 'C50.31', 'C50.41', 'C50.91'],
    therapy_area: 'oncology',
    us_prevalence: 85000,
    us_incidence: 55000,
    prevalence_source: 'American Cancer Society 2024; SEER Database; HER2 prevalence in breast cancer (~20%)',
    diagnosis_rate: 0.95,
    treatment_rate: 0.92,
    cagr_5yr: 8.0,
    major_competitors: [
      'Herceptin (trastuzumab, Roche) + biosimilars',
      'Perjeta (pertuzumab, Roche)',
      'Enhertu (trastuzumab deruxtecan, Daiichi Sankyo) — ADC',
      'Kadcyla (T-DM1, Roche) — ADC',
      'Tukysa (tucatinib, Seagen)',
      'Nerlynx (neratinib, Puma Biotech)',
      'Phesgo (pertuzumab/trastuzumab SC, Roche)',
    ],
    market_growth_driver: 'Enhertu expanding across HER2-low, ADC class dominance, neoadjuvant optimization, brain metastasis penetration (tucatinib), HER2-low/ultralow paradigm',
    therapy_area_pricing_context: 'ADCs at $150K-$200K annually; targeted agents $80K-$150K. HER2-low expansion dramatically increases addressable population.',
  },

  {
    name: 'HR+/HER2- Breast Cancer',
    synonyms: ['HR+ breast cancer', 'HR-positive breast cancer', 'hormone receptor positive breast cancer', 'ER+ breast cancer', 'luminal breast cancer', 'HR+/HER2-negative breast cancer'],
    icd10_codes: ['C50.01', 'C50.11', 'C50.21', 'C50.31', 'C50.41', 'C50.91'],
    therapy_area: 'oncology',
    us_prevalence: 600000,
    us_incidence: 210000,
    prevalence_source: 'American Cancer Society 2024; SEER Database; HR+/HER2- accounts for ~70% of all breast cancers',
    diagnosis_rate: 0.95,
    treatment_rate: 0.90,
    cagr_5yr: 6.5,
    major_competitors: [
      'Ibrance (palbociclib, Pfizer) — CDK4/6 inhibitor (going generic)',
      'Verzenio (abemaciclib, Eli Lilly) — CDK4/6 inhibitor',
      'Kisqali (ribociclib, Novartis) — CDK4/6 inhibitor',
      'Faslodex (fulvestrant, AstraZeneca) — ER degrader',
      'Orserdu (elacestrant, Stemline) — oral SERD',
      'ARV-471 (vepdegestrant, Arvinas/Pfizer) — PROTAC ER degrader',
      'Capivasertib (AstraZeneca) — AKT inhibitor',
    ],
    market_growth_driver: 'CDK4/6 inhibitor market maturation with Ibrance LOE, oral SERD/PROTAC competition, adjuvant CDK4/6i expansion (monarchE), AKT/PI3K pathway targeting, ESR1 mutation-directed therapy',
    therapy_area_pricing_context: 'CDK4/6 inhibitors at $150K-$180K annually; Ibrance generics expected to reduce class pricing. Novel SERDs/PROTACs at $120K-$200K. Chronic therapy with long treatment duration.',
  },

  {
    name: 'Gastric Cancer',
    synonyms: ['stomach cancer', 'gastric carcinoma', 'gastric adenocarcinoma', 'advanced gastric cancer'],
    icd10_codes: ['C16.0', 'C16.1', 'C16.2', 'C16.3', 'C16.4', 'C16.5', 'C16.6', 'C16.8', 'C16.9'],
    therapy_area: 'oncology',
    us_prevalence: 40000,
    us_incidence: 26890,
    prevalence_source: 'American Cancer Society 2024; SEER Database',
    diagnosis_rate: 0.85,
    treatment_rate: 0.78,
    cagr_5yr: 9.2,
    major_competitors: [
      'Keytruda (pembrolizumab, MSD)',
      'Opdivo (nivolumab, BMS)',
      'Enhertu (trastuzumab deruxtecan, Daiichi Sankyo) — HER2+',
      'Herceptin (trastuzumab, Roche) — HER2+',
      'Zolbetuximab (Astellas) — CLDN18.2+',
      'FOLFOX/CAPOX regimen (generic)',
    ],
    market_growth_driver: 'Claudin 18.2 targeted therapy, HER2 ADC expansion, immunotherapy frontline combinations, biomarker-stratified approaches, perioperative IO',
    therapy_area_pricing_context: 'IO agents $150K+ annually; novel targets (CLDN18.2) can command premium. Rising global incidence creates expansion opportunity.',
  },

  {
    name: 'Basal Cell Carcinoma',
    synonyms: ['BCC', 'basal cell carcinoma', 'basal cell skin cancer', 'advanced BCC', 'locally advanced BCC'],
    icd10_codes: ['C44.01', 'C44.11', 'C44.21', 'C44.31', 'C44.41', 'C44.91'],
    therapy_area: 'oncology',
    us_prevalence: 3300000,
    us_incidence: 3600000,
    prevalence_source: 'American Cancer Society 2024; Skin Cancer Foundation; AAD',
    diagnosis_rate: 0.92,
    treatment_rate: 0.95,
    cagr_5yr: 6.0,
    major_competitors: [
      'Erivedge (vismodegib, Roche) — Hedgehog inhibitor',
      'Odomzo (sonidegib, Sun Pharma) — Hedgehog inhibitor',
      'Libtayo (cemiplimab, Regeneron/Sanofi) — PD-1 inhibitor',
      'Surgical excision (standard of care)',
      'Mohs surgery',
    ],
    market_growth_driver: 'IO for advanced/metastatic BCC, Hedgehog inhibitor limitations driving IO adoption, topical immunotherapy approaches, neoadjuvant IO before surgery',
    therapy_area_pricing_context: 'Hedgehog inhibitors $10K-$12K/month; IO at $150K annually. Most patients treated surgically; pharmacotherapy for advanced disease only.',
  },

  {
    name: 'Cutaneous Squamous Cell Carcinoma',
    synonyms: ['cSCC', 'cutaneous SCC', 'squamous cell skin cancer', 'advanced cSCC', 'metastatic cSCC'],
    icd10_codes: ['C44.02', 'C44.12', 'C44.22', 'C44.32', 'C44.42', 'C44.92'],
    therapy_area: 'oncology',
    us_prevalence: 1800000,
    us_incidence: 1800000,
    prevalence_source: 'American Cancer Society 2024; Skin Cancer Foundation; published estimates',
    diagnosis_rate: 0.90,
    treatment_rate: 0.95,
    cagr_5yr: 8.0,
    major_competitors: [
      'Libtayo (cemiplimab, Regeneron/Sanofi) — PD-1 inhibitor, first approved for cSCC',
      'Keytruda (pembrolizumab, MSD)',
      'Surgical excision (standard of care)',
    ],
    market_growth_driver: 'IO for advanced cSCC, neoadjuvant IO before surgery, adjuvant immunotherapy for high-risk resected disease, combination approaches',
    therapy_area_pricing_context: 'IO at $150K annually for advanced disease. Most treated surgically; expanding pharmacotherapy opportunity in high-risk/advanced setting.',
  },

  // ──────────────────────────────────────────
  // NEUROLOGY / CNS
  // ──────────────────────────────────────────
  {
    name: "Alzheimer's Disease",
    synonyms: ["Alzheimer's", 'AD', 'Alzheimer disease', 'dementia Alzheimer type'],
    icd10_codes: ['G30', 'G30.0', 'G30.1', 'G30.8', 'G30.9'],
    therapy_area: 'neurology',
    us_prevalence: 6800000,
    us_incidence: 500000,
    prevalence_source: "Alzheimer's Association 2024 Facts and Figures",
    diagnosis_rate: 0.45,        // Many undiagnosed; early detection remains challenge
    treatment_rate: 0.60,        // Of diagnosed, many on symptomatic treatment
    cagr_5yr: 14.2,
    major_competitors: [
      'Leqembi (lecanemab, Eisai/Biogen)',
      'Kisunla (donanemab, Eli Lilly)',
      'Memantine (generic)',
      'Donepezil (generic)',
    ],
    market_growth_driver: 'Anti-amyloid approvals opening premium treatment market, early detection via blood biomarkers, pipeline for early-stage disease',
    therapy_area_pricing_context: "Leqembi at $26,500/year sets early precedent; anti-tau and next-gen modalities could command $30K-$80K annually",
  },

  {
    name: "Parkinson's Disease",
    synonyms: ["Parkinson's", 'PD', 'Parkinson disease', 'idiopathic Parkinson'],
    icd10_codes: ['G20'],
    therapy_area: 'neurology',
    us_prevalence: 1000000,
    us_incidence: 90000,
    prevalence_source: "Parkinson's Foundation 2024; NPF National Parkinson Foundation",
    diagnosis_rate: 0.75,
    treatment_rate: 0.88,
    cagr_5yr: 8.4,
    major_competitors: [
      'Levodopa/Carbidopa (generic)',
      'Rytary (IPX066, Amneal)',
      'Xadago (safinamide, Supernus)',
      'Ongentys (opicapone, Neurocrine)',
      'Inbrija (levodopa inhalation, Acorda)',
    ],
    market_growth_driver: 'Disease-modifying therapy opportunity (alpha-synuclein, LRRK2), device-aided therapies, digital health integration',
    therapy_area_pricing_context: 'Symptomatic drugs face generic competition; disease-modifying therapy could command $40K-$100K annually',
  },

  {
    name: 'Amyotrophic Lateral Sclerosis',
    synonyms: ['ALS', 'Lou Gehrig Disease', 'motor neuron disease', 'MND'],
    icd10_codes: ['G12.21'],
    therapy_area: 'neurology',
    us_prevalence: 32000,
    us_incidence: 16000,
    prevalence_source: 'ALS Association 2024; CDC ALS Registry',
    diagnosis_rate: 0.88,
    treatment_rate: 0.82,
    cagr_5yr: 15.2,
    major_competitors: [
      'Radicava (edaravone, Mitsubishi Tanabe)',
      'Relyvrio (phenylbutyrate+tauro, Amylyx) — withdrawn US market 2024',
      'Qalsody (tofersen, Biogen, SOD1-ALS only)',
      'Riluzole (generic)',
    ],
    market_growth_driver: 'Genetic subtype targeting (SOD1, FUS, TDP-43), gene therapy approaches, high unmet need, rare disease pricing',
    therapy_area_pricing_context: 'Rare neurological disease; $100K-$300K annually. Orphan designation available.',
  },

  {
    name: 'Multiple Sclerosis',
    synonyms: ['MS', 'relapsing MS', 'RRMS', 'relapsing-remitting multiple sclerosis', 'PPMS', 'progressive MS'],
    icd10_codes: ['G35'],
    therapy_area: 'neurology',
    us_prevalence: 1000000,
    us_incidence: 10000,
    prevalence_source: 'National MS Society 2024; MSIF Atlas',
    diagnosis_rate: 0.90,
    treatment_rate: 0.82,
    cagr_5yr: 5.8,
    major_competitors: [
      'Ocrevus (ocrelizumab, Roche)',
      'Kesimpta (ofatumumab, Novartis)',
      'Tysabri (natalizumab, Biogen)',
      'Mavenclad (cladribine, EMD Serono)',
      'Zeposia (ozanimod, BMS)',
      'Fenway (ponesimod, Janssen)',
    ],
    market_growth_driver: 'Progressive MS treatment gap, neuroprotection/repair targets, subtype-specific biologics',
    therapy_area_pricing_context: 'Highly competitive; Ocrevus set $65K/year benchmark. Novel mechanisms with neuroprotection claims could command premium',
  },

  {
    name: 'Spinal Muscular Atrophy',
    synonyms: ['SMA', 'spinal muscular atrophy type 1', 'SMA1', 'SMA2', 'SMA3'],
    icd10_codes: ['G12.0', 'G12.1'],
    therapy_area: 'neurology',
    us_prevalence: 10000,
    us_incidence: 600,
    prevalence_source: 'SMA Foundation; Cure SMA 2024',
    diagnosis_rate: 0.95,        // Newborn screening expanding
    treatment_rate: 0.90,
    cagr_5yr: 18.5,
    major_competitors: [
      'Zolgensma (onasemnogene, Novartis) — $2.1M gene therapy',
      'Spinraza (nusinersen, Biogen) — $125K/year',
      'Evrysdi (risdiplam, Roche) — $340K/year',
    ],
    market_growth_driver: 'Gene therapy precedent, combination approaches, next-gen RNA splicing therapies, newborn screening expansion',
    therapy_area_pricing_context: 'Ultra-rare; gene therapy sets multi-million dollar precedent. Chronic treatments $120K-$340K annually.',
  },

  {
    name: 'Epilepsy',
    synonyms: ['epilepsy', 'treatment-resistant epilepsy', 'TRE', 'refractory epilepsy', 'focal epilepsy', 'generalized epilepsy'],
    icd10_codes: ['G40.0', 'G40.1', 'G40.2', 'G40.3', 'G40.4', 'G40.5', 'G40.8', 'G40.9'],
    therapy_area: 'neurology',
    us_prevalence: 3400000,
    us_incidence: 150000,
    prevalence_source: 'Epilepsy Foundation 2024; CDC BRFSS Epilepsy Module',
    diagnosis_rate: 0.82,
    treatment_rate: 0.75,
    cagr_5yr: 5.5,
    major_competitors: [
      'Briviact (brivaracetam, UCB)',
      'Fycompa (perampanel, Eisai)',
      'Xcopri (cenobamate, SK Life Science)',
      'Epidiolex (cannabidiol, Jazz Pharma)',
      'Levetiracetam (generic)',
      'Lamotrigine (generic)',
      'Carbamazepine (generic)',
    ],
    market_growth_driver: 'Treatment-resistant epilepsy (30% of patients), gene therapy for monogenic epilepsies, precision medicine approaches, novel mechanisms',
    therapy_area_pricing_context: 'Broad generic competition in well-controlled epilepsy; novel agents for TRE at $30K-$80K annually. Gene therapies for monogenic forms could command $500K+.',
  },

  {
    name: 'Migraine',
    synonyms: ['migraine', 'chronic migraine', 'episodic migraine', 'migraine with aura', 'migraine without aura', 'CM'],
    icd10_codes: ['G43.0', 'G43.1', 'G43.7', 'G43.9'],
    therapy_area: 'neurology',
    us_prevalence: 39000000,
    us_incidence: 4500000,
    prevalence_source: 'American Migraine Foundation 2024; AHS; GBD Study',
    diagnosis_rate: 0.50,
    treatment_rate: 0.48,
    cagr_5yr: 9.5,
    major_competitors: [
      'Aimovig (erenumab, Amgen/Novartis) — CGRP mAb',
      'Ajovy (fremanezumab, Teva) — CGRP mAb',
      'Emgality (galcanezumab, Eli Lilly) — CGRP mAb',
      'Vyepti (eptinezumab, Lundbeck) — CGRP mAb IV',
      'Nurtec ODT (rimegepant, Pfizer) — CGRP receptor antagonist',
      'Ubrelvy (ubrogepant, AbbVie) — CGRP receptor antagonist',
      'Qulipta (atogepant, AbbVie) — CGRP receptor antagonist oral preventive',
      'Sumatriptan (generic)',
    ],
    market_growth_driver: 'Massive underdiagnosed/undertreated population, CGRP class expansion, oral preventives improving access, dual-action acute+preventive use',
    therapy_area_pricing_context: 'CGRP mAbs at $6K-$7K annually; oral gepants at $8K-$10K annually. Massive market size compensates for moderate pricing.',
  },

  {
    name: "Huntington's Disease",
    synonyms: ["Huntington's", 'HD', 'Huntington disease', 'Huntington chorea'],
    icd10_codes: ['G10'],
    therapy_area: 'neurology',
    us_prevalence: 41000,
    us_incidence: 3500,
    prevalence_source: 'Huntington Disease Society of America 2024; HDSA',
    diagnosis_rate: 0.85,
    treatment_rate: 0.70,
    cagr_5yr: 15.0,
    major_competitors: [
      'Austedo (deutetrabenazine, Teva) — chorea',
      'Xenazine (tetrabenazine, Lundbeck) — chorea',
      'Tominersen (Roche) — HTT-lowering ASO, Phase 3 discontinued then restarted in subset',
    ],
    market_growth_driver: 'Huntingtin-lowering approaches (ASO, RNA interference, gene therapy), no disease-modifying therapy approved, genetic testing expansion',
    therapy_area_pricing_context: 'Rare neurodegeneration; symptomatic agents $50K-$80K. Disease-modifying therapy could command $200K-$500K annually.',
  },

  {
    name: "Friedreich's Ataxia",
    synonyms: ['FRDA', 'Friedreich ataxia', 'FA', 'Friedreich disease'],
    icd10_codes: ['G11.1'],
    therapy_area: 'neurology',
    us_prevalence: 5000,
    us_incidence: 600,
    prevalence_source: 'Friedreich Ataxia Research Alliance 2024; FARA',
    diagnosis_rate: 0.90,
    treatment_rate: 0.75,
    cagr_5yr: 20.0,
    major_competitors: [
      'Skyclarys (omaveloxolone, Reata/Biogen) — first FDA-approved FRDA therapy',
      'Idebenone (off-label in some countries)',
    ],
    market_growth_driver: 'First approval sets precedent, frataxin replacement gene therapy, frataxin protein replacement, combination approaches',
    therapy_area_pricing_context: 'Skyclarys at ~$370K annually. Ultra-rare; orphan drug pricing fully applicable. Gene therapy could be $2M+ one-time.',
  },

  {
    name: 'Progressive Supranuclear Palsy',
    synonyms: ['PSP', 'progressive supranuclear palsy', 'Steele-Richardson-Olszewski syndrome'],
    icd10_codes: ['G23.1'],
    therapy_area: 'neurology',
    us_prevalence: 30000,
    us_incidence: 5000,
    prevalence_source: 'CurePSP Foundation 2024; published epidemiology estimates',
    diagnosis_rate: 0.50,
    treatment_rate: 0.40,
    cagr_5yr: 12.0,
    major_competitors: [
      'No FDA-approved therapies',
      'Levodopa (generic, limited efficacy)',
      'Coenzyme Q10 (supplement)',
    ],
    market_growth_driver: 'Tau-targeted therapies from AD pipeline, complete treatment void, anti-tau antibodies and ASOs in clinical development',
    therapy_area_pricing_context: 'No approved therapy; first-in-disease agent could command $100K-$300K annually. Orphan designation likely.',
  },

  {
    name: 'Myasthenia Gravis',
    synonyms: ['MG', 'myasthenia gravis', 'generalized myasthenia gravis', 'gMG', 'AChR+ MG'],
    icd10_codes: ['G70.0', 'G70.00', 'G70.01'],
    therapy_area: 'neurology',
    us_prevalence: 60000,
    us_incidence: 5000,
    prevalence_source: 'Myasthenia Gravis Foundation of America 2024; MGFA',
    diagnosis_rate: 0.80,
    treatment_rate: 0.85,
    cagr_5yr: 18.0,
    major_competitors: [
      'Vyvgart (efgartigimod, argenx) — FcRn inhibitor',
      'Ultomiris (ravulizumab, Alexion) — complement C5 inhibitor',
      'Soliris (eculizumab, Alexion) — complement C5 inhibitor',
      'Rystiggo (rozanolixizumab, UCB) — FcRn inhibitor',
      'Pyridostigmine (generic)',
      'Azathioprine (generic)',
      'Mycophenolate (generic)',
    ],
    market_growth_driver: 'FcRn inhibitor class expansion, complement inhibition, CD19-targeted B cell depletion, neonatal Fc receptor blockade advancing rapidly',
    therapy_area_pricing_context: 'Vyvgart at ~$310K annually; complement inhibitors at $300K-$500K. Premium rare neuroimmunology pricing.',
  },

  {
    name: 'Neuromyelitis Optica Spectrum Disorder',
    synonyms: ['NMOSD', 'NMO', 'neuromyelitis optica', "Devic's disease", 'AQP4+ NMOSD'],
    icd10_codes: ['G36.0'],
    therapy_area: 'neurology',
    us_prevalence: 15000,
    us_incidence: 1500,
    prevalence_source: 'Guthy-Jackson Charitable Foundation 2024; published epidemiology',
    diagnosis_rate: 0.75,
    treatment_rate: 0.85,
    cagr_5yr: 14.0,
    major_competitors: [
      'Soliris (eculizumab, Alexion)',
      'Enspryng (satralizumab, Roche) — anti-IL-6R',
      'Uplizna (inebilizumab, Amgen) — anti-CD19',
    ],
    market_growth_driver: 'Three approved therapies in 5 years, AQP4-seronegative disease unmet need, combination approaches, relapse prevention optimization',
    therapy_area_pricing_context: 'Ultra-rare neuroimmunology; Soliris at $400K+ annually, Enspryng at $250K, Uplizna at $300K. Orphan drug premium.',
  },

  {
    name: 'Chronic Inflammatory Demyelinating Polyneuropathy',
    synonyms: ['CIDP', 'chronic inflammatory demyelinating polyneuropathy', 'chronic inflammatory neuropathy'],
    icd10_codes: ['G61.81'],
    therapy_area: 'neurology',
    us_prevalence: 30000,
    us_incidence: 3000,
    prevalence_source: 'GBS-CIDP Foundation 2024; published epidemiology estimates',
    diagnosis_rate: 0.65,
    treatment_rate: 0.80,
    cagr_5yr: 12.0,
    major_competitors: [
      'IVIg (Privigen, Gamunex, etc.) — immunoglobulin',
      'SCIg (Hizentra, CSL Behring)',
      'Vyvgart Hytrulo (efgartigimod, argenx) — FcRn inhibitor',
      'Corticosteroids (generic)',
    ],
    market_growth_driver: 'FcRn inhibitor disruption of IVIg market, complement inhibitors, targeted B cell therapies, diagnosis rate improvement',
    therapy_area_pricing_context: 'IVIg at $50K-$100K annually; FcRn inhibitors at ~$310K. Shifting from blood product to targeted biologic paradigm.',
  },

  {
    name: 'Transthyretin Amyloid Cardiomyopathy',
    synonyms: ['ATTR-CM', 'TTR cardiomyopathy', 'transthyretin amyloidosis', 'ATTR amyloidosis', 'cardiac amyloidosis'],
    icd10_codes: ['E85.4', 'E85.82'],
    therapy_area: 'neurology',
    us_prevalence: 300000,
    us_incidence: 60000,
    prevalence_source: 'Amyloidosis Foundation 2024; published prevalence estimates (likely underdiagnosed)',
    diagnosis_rate: 0.15,
    treatment_rate: 0.65,
    cagr_5yr: 28.0,
    major_competitors: [
      'Vyndaqel/Vyndamax (tafamidis, Pfizer) — TTR stabilizer',
      'Onpattro (patisiran, Alnylam) — RNAi',
      'Amvuttra (vutrisiran, Alnylam) — RNAi',
      'ATTR-silencer (eplontersen, Ionis/AstraZeneca)',
    ],
    market_growth_driver: 'Massive underdiagnosis (est. 300K+ patients vs <50K diagnosed), cardiac imaging screening, TTR silencing/knockdown competition, combination approaches',
    therapy_area_pricing_context: 'Vyndaqel at $225K annually; TTR silencers at $200K-$450K. Rapidly expanding diagnosed population driving market growth.',
  },

  {
    name: 'Essential Tremor',
    synonyms: ['ET', 'essential tremor', 'benign essential tremor', 'familial tremor'],
    icd10_codes: ['G25.0'],
    therapy_area: 'neurology',
    us_prevalence: 7000000,
    us_incidence: 500000,
    prevalence_source: 'International Essential Tremor Foundation 2024; published epidemiology',
    diagnosis_rate: 0.50,
    treatment_rate: 0.45,
    cagr_5yr: 6.0,
    major_competitors: [
      'Propranolol (generic)',
      'Primidone (generic)',
      'Gabapentin (generic, off-label)',
      'Focused ultrasound (Insightec/Exablate)',
      'DBS (Medtronic, Abbott, Boston Scientific)',
    ],
    market_growth_driver: 'Massive undertreated population, non-invasive neurostimulation devices, T-type calcium channel modulators, novel mechanism drugs in development',
    therapy_area_pricing_context: 'Generic first-line therapy; novel pharmacotherapy could command $15K-$30K annually. Device approaches $30K-$100K one-time.',
  },

  {
    name: 'Narcolepsy',
    synonyms: ['narcolepsy', 'narcolepsy type 1', 'narcolepsy type 2', 'narcolepsy with cataplexy', 'NT1', 'NT2'],
    icd10_codes: ['G47.41', 'G47.419', 'G47.42'],
    therapy_area: 'neurology',
    us_prevalence: 200000,
    us_incidence: 15000,
    prevalence_source: 'Narcolepsy Network 2024; published epidemiology; Wake Up Narcolepsy',
    diagnosis_rate: 0.25,
    treatment_rate: 0.70,
    cagr_5yr: 10.0,
    major_competitors: [
      'Xyrem (sodium oxybate, Jazz Pharma)',
      'Xywav (lower-sodium oxybate, Jazz Pharma)',
      'Wakix (pitolisant, Harmony Biosciences) — histamine H3 inverse agonist',
      'Sunosi (solriamfetol, Jazz Pharma)',
      'Modafinil/Armodafinil (generic)',
    ],
    market_growth_driver: 'Orexin receptor agonists in development (restoring deficient neuropeptide), improved diagnosis rates, novel wake-promoting agents',
    therapy_area_pricing_context: 'Xywav at $120K+ annually; Wakix at $120K. Rare sleep disorder supports premium pricing. Orexin agonists could command $80K-$150K.',
  },

  {
    name: 'Rett Syndrome',
    synonyms: ['Rett syndrome', 'Rett disorder', 'MECP2 disorder', 'RTT'],
    icd10_codes: ['F84.2'],
    therapy_area: 'neurology',
    us_prevalence: 10000,
    us_incidence: 500,
    prevalence_source: 'International Rett Syndrome Foundation 2024; IRSF; Rett Syndrome Research Trust',
    diagnosis_rate: 0.90,
    treatment_rate: 0.70,
    cagr_5yr: 18.0,
    major_competitors: [
      'Daybue (trofinetide, Acadia Pharmaceuticals) — first FDA-approved Rett therapy',
    ],
    market_growth_driver: 'First approval opens market, gene therapy approaches targeting MECP2, combination strategies, improved survival creating larger prevalent pool',
    therapy_area_pricing_context: 'Daybue at $576K annually. Ultra-rare pediatric neurodevelopmental disorder; orphan pricing fully applicable.',
  },

  {
    name: 'Angelman Syndrome',
    synonyms: ['AS', 'Angelman syndrome', 'UBE3A deficiency', 'happy puppet syndrome'],
    icd10_codes: ['Q93.51'],
    therapy_area: 'neurology',
    us_prevalence: 15000,
    us_incidence: 1000,
    prevalence_source: 'Angelman Syndrome Foundation 2024; published epidemiology',
    diagnosis_rate: 0.80,
    treatment_rate: 0.50,
    cagr_5yr: 20.0,
    major_competitors: [
      'No FDA-approved therapies for core symptoms',
      'Anticonvulsants (generic, for seizures)',
      'Gene therapy candidates in clinical trials (GeneTx/Ultragenyx, Roche)',
    ],
    market_growth_driver: 'UBE3A gene reactivation via ASO, gene replacement therapy, no approved disease-modifying treatment creates massive opportunity',
    therapy_area_pricing_context: 'Ultra-rare pediatric; gene therapy could command $2M+ one-time. Chronic therapy $300K-$500K annually.',
  },

  {
    name: 'Dravet Syndrome',
    synonyms: ['Dravet syndrome', 'SMEI', 'severe myoclonic epilepsy of infancy', 'SCN1A epilepsy'],
    icd10_codes: ['G40.41', 'G40.42'],
    therapy_area: 'neurology',
    us_prevalence: 15000,
    us_incidence: 1200,
    prevalence_source: 'Dravet Syndrome Foundation 2024; published epidemiology estimates',
    diagnosis_rate: 0.85,
    treatment_rate: 0.88,
    cagr_5yr: 12.0,
    major_competitors: [
      'Epidiolex (cannabidiol, Jazz Pharma)',
      'Fintepla (fenfluramine, UCB)',
      'Diacomit (stiripentol, Biocodex)',
      'Valproate (generic)',
      'Clobazam (generic)',
    ],
    market_growth_driver: 'Precision medicine (SCN1A-targeted gene therapy), antisense oligonucleotides, novel anticonvulsant mechanisms, SUDEP prevention',
    therapy_area_pricing_context: 'Rare pediatric epilepsy; branded agents $30K-$80K annually. Gene therapy approaches could command $1M+.',
  },

  {
    name: 'Tardive Dyskinesia',
    synonyms: ['TD', 'tardive dyskinesia', 'drug-induced dyskinesia', 'neuroleptic-induced tardive dyskinesia'],
    icd10_codes: ['G24.01'],
    therapy_area: 'neurology',
    us_prevalence: 600000,
    us_incidence: 60000,
    prevalence_source: 'AJMC Tardive Dyskinesia estimates 2024; published epidemiology',
    diagnosis_rate: 0.40,
    treatment_rate: 0.35,
    cagr_5yr: 12.0,
    major_competitors: [
      'Ingrezza (valbenazine, Neurocrine Biosciences) — VMAT2 inhibitor',
      'Austedo (deutetrabenazine, Teva) — VMAT2 inhibitor',
    ],
    market_growth_driver: 'Massive underdiagnosis, increasing antipsychotic use expanding at-risk population, VMAT2 class penetration growth, awareness campaigns',
    therapy_area_pricing_context: 'Ingrezza at ~$85K annually; Austedo at ~$80K. Large untreated population with room for market expansion.',
  },

  {
    name: 'Lennox-Gastaut Syndrome',
    synonyms: ['LGS', 'Lennox-Gastaut syndrome', 'Lennox-Gastaut epilepsy'],
    icd10_codes: ['G40.81', 'G40.811', 'G40.812'],
    therapy_area: 'neurology',
    us_prevalence: 30000,
    us_incidence: 2500,
    prevalence_source: 'LGS Foundation 2024; published epilepsy epidemiology',
    diagnosis_rate: 0.85,
    treatment_rate: 0.90,
    cagr_5yr: 10.0,
    major_competitors: [
      'Epidiolex (cannabidiol, Jazz Pharma)',
      'Fintepla (fenfluramine, UCB)',
      'Banzel (rufinamide, Eisai)',
      'Onfi (clobazam, Lundbeck)',
      'Lamotrigine (generic)',
      'Valproate (generic)',
      'VNS therapy (LivaNova) — device',
    ],
    market_growth_driver: 'Cannabidiol class expansion, precision medicine for genetic subtypes, novel anticonvulsant mechanisms, neuromodulation devices, disease modification approaches',
    therapy_area_pricing_context: 'Epidiolex at $32K annually; Fintepla at $80K+. Rare pediatric epilepsy with orphan pricing. High polypharmacy rates.',
  },

  {
    name: 'Duchenne Muscular Dystrophy - CNS Manifestations',
    synonyms: ['DMD cognitive', 'DMD neurocognitive', 'DMD behavioral'],
    icd10_codes: ['G71.01'],
    therapy_area: 'neurology',
    us_prevalence: 15000,
    us_incidence: 500,
    prevalence_source: 'Parent Project Muscular Dystrophy 2024; published estimates',
    diagnosis_rate: 0.50,
    treatment_rate: 0.20,
    cagr_5yr: 15.0,
    major_competitors: [
      'No FDA-approved therapies for CNS manifestations',
      'Behavioral therapy (standard of care)',
      'SSRIs (off-label, generic)',
    ],
    market_growth_driver: 'CNS manifestations gaining recognition, dystrophin restoration in brain, antisense oligonucleotides crossing BBB, cognitive endpoints in trials',
    therapy_area_pricing_context: 'No current market; novel CNS-targeting DMD therapies could leverage rare disease/pediatric pricing at $200K+ annually.',
  },

  {
    name: 'Trigeminal Neuralgia',
    synonyms: ['TN', 'trigeminal neuralgia', 'tic douloureux', 'facial pain', 'trigeminal neuropathic pain'],
    icd10_codes: ['G50.0'],
    therapy_area: 'neurology',
    us_prevalence: 150000,
    us_incidence: 15000,
    prevalence_source: 'Facial Pain Association 2024; published epidemiology estimates',
    diagnosis_rate: 0.70,
    treatment_rate: 0.80,
    cagr_5yr: 7.0,
    major_competitors: [
      'Carbamazepine (generic) — first-line',
      'Oxcarbazepine (generic)',
      'Baclofen (generic)',
      'Microvascular decompression (surgical)',
      'Gamma knife radiosurgery',
    ],
    market_growth_driver: 'Nav1.7 selective inhibitors in development, botulinum toxin approaches, novel sodium channel blockers, unmet need for refractory pain',
    therapy_area_pricing_context: 'Generic first-line therapy; novel selective Nav blockers could command $20K-$50K annually. Surgical alternatives $15K-$30K one-time.',
  },

  {
    name: 'Charcot-Marie-Tooth Disease',
    synonyms: ['CMT', 'Charcot-Marie-Tooth', 'hereditary motor sensory neuropathy', 'HMSN', 'CMT1A', 'CMT2'],
    icd10_codes: ['G60.0'],
    therapy_area: 'neurology',
    us_prevalence: 150000,
    us_incidence: 5000,
    prevalence_source: 'CMT Association 2024; CMTA; published epidemiology',
    diagnosis_rate: 0.65,
    treatment_rate: 0.30,
    cagr_5yr: 18.0,
    major_competitors: [
      'No FDA-approved disease-modifying therapies',
      'Physical therapy (standard of care)',
      'Orthotic devices',
      'PXT3003 (Pharnext) — investigational combination',
    ],
    market_growth_driver: 'Complete treatment void for disease modification, gene therapy targeting PMP22, RNA-based approaches, neuroprotective agents, large rare disease population',
    therapy_area_pricing_context: 'No current market; first approved disease-modifying therapy could command $100K-$300K annually. Gene therapy $1M+ one-time.',
  },

  // ──────────────────────────────────────────
  // RARE DISEASE
  // ──────────────────────────────────────────
  {
    name: 'Duchenne Muscular Dystrophy',
    synonyms: ['DMD', 'Duchenne MD', 'X-linked muscular dystrophy'],
    icd10_codes: ['G71.01'],
    therapy_area: 'rare_disease',
    us_prevalence: 15000,
    us_incidence: 500,
    prevalence_source: 'Parent Project Muscular Dystrophy 2024; CDC',
    diagnosis_rate: 0.92,
    treatment_rate: 0.85,
    cagr_5yr: 22.0,
    major_competitors: [
      'Elevidys (delandistrogene moxeparvovec, Sarepta) — gene therapy',
      'Exondys 51 (eteplirsen, Sarepta)',
      'Vyondys 53 (golodirsen, Sarepta)',
      'Amondys 45 (casimersen, Sarepta)',
      'Viltepso (viltolarsen, NS Pharma)',
      'Corticosteroids (standard of care)',
    ],
    market_growth_driver: 'Gene therapy expansion (all patients), exon skipping expansion, stop codon readthrough, combination approaches',
    therapy_area_pricing_context: 'Ultra-rare, pediatric; gene therapies $3M+. Chronic therapies $500K-$1M annually.',
  },

  {
    name: 'Cystic Fibrosis',
    synonyms: ['CF', 'cystic fibrosis', 'CF lung disease'],
    icd10_codes: ['E84', 'E84.0', 'E84.1', 'E84.8', 'E84.9'],
    therapy_area: 'rare_disease',
    us_prevalence: 35000,
    us_incidence: 1000,
    prevalence_source: 'Cystic Fibrosis Foundation 2024 Patient Registry',
    diagnosis_rate: 0.98,        // Newborn screening near-universal
    treatment_rate: 0.92,
    cagr_5yr: 6.5,               // Trikafta has transformed market
    major_competitors: [
      'Trikafta (elexacaftor/tezacaftor/ivacaftor, Vertex)',
      'Symdeko (tezacaftor/ivacaftor, Vertex)',
      'Orkambi (lumacaftor/ivacaftor, Vertex)',
      'Kalydeco (ivacaftor, Vertex)',
    ],
    market_growth_driver: 'Patients not eligible for current modulators, next-gen modulators, mRNA/gene therapy, combination approaches',
    therapy_area_pricing_context: 'Vertex dominant at $300K+ annually; gene therapy could be single curative dose',
  },

  {
    name: 'Gaucher Disease',
    synonyms: ['Gaucher disease', 'GD', 'Gaucher disease type 1', 'glucocerebrosidase deficiency'],
    icd10_codes: ['E75.22'],
    therapy_area: 'rare_disease',
    us_prevalence: 6000,
    us_incidence: 200,
    prevalence_source: 'National Gaucher Foundation 2024; published epidemiology',
    diagnosis_rate: 0.85,
    treatment_rate: 0.90,
    cagr_5yr: 4.5,
    major_competitors: [
      'Cerezyme (imiglucerase, Sanofi) — ERT',
      'VPRIV (velaglucerase alfa, Takeda) — ERT',
      'Cerdelga (eliglustat, Sanofi) — oral SRT',
      'Zavesca (miglustat, Janssen) — oral SRT',
    ],
    market_growth_driver: 'Gene therapy approaches, oral substrate reduction expansion, next-gen ERT, CNS-penetrant therapies for neuronopathic forms',
    therapy_area_pricing_context: 'ERT at $200K-$400K annually; oral SRT at $300K+. Established ultra-rare disease pricing paradigm.',
  },

  {
    name: 'Pompe Disease',
    synonyms: ['Pompe disease', 'acid maltase deficiency', 'GAA deficiency', 'glycogen storage disease type II', 'GSD II'],
    icd10_codes: ['E74.02'],
    therapy_area: 'rare_disease',
    us_prevalence: 5000,
    us_incidence: 300,
    prevalence_source: 'Acid Maltase Deficiency Association 2024; Pompe Community; published epidemiology',
    diagnosis_rate: 0.80,
    treatment_rate: 0.85,
    cagr_5yr: 8.0,
    major_competitors: [
      'Lumizyme (alglucosidase alfa, Sanofi) — ERT',
      'Nexviazyme (avalglucosidase alfa, Sanofi) — next-gen ERT',
      'Myozyme (alglucosidase alfa, Sanofi) — infantile onset',
    ],
    market_growth_driver: 'Next-gen ERT with improved uptake, gene therapy (AAV-based), substrate reduction approaches, combination ERT+chaperone strategies',
    therapy_area_pricing_context: 'ERT at $300K-$600K annually; ultra-rare orphan pricing. Gene therapy approaching $2M+ one-time.',
  },

  {
    name: 'Fabry Disease',
    synonyms: ['Fabry disease', 'Anderson-Fabry disease', 'alpha-galactosidase A deficiency', 'GLA deficiency'],
    icd10_codes: ['E75.21'],
    therapy_area: 'rare_disease',
    us_prevalence: 10000,
    us_incidence: 600,
    prevalence_source: 'Fabry Support & Information Group 2024; published newborn screening data',
    diagnosis_rate: 0.60,
    treatment_rate: 0.80,
    cagr_5yr: 7.5,
    major_competitors: [
      'Fabrazyme (agalsidase beta, Sanofi) — ERT',
      'Galafold (migalastat, Amicus) — oral chaperone (amenable mutations)',
      'Replagal (agalsidase alfa, Takeda) — ERT (not approved in US)',
    ],
    market_growth_driver: 'Newborn screening expansion increasing diagnosed pool, gene therapy approaches, substrate reduction, next-gen ERT with improved tissue penetration',
    therapy_area_pricing_context: 'ERT at $200K-$350K annually; Galafold at $315K annually. Orphan drug pricing well-established.',
  },

  {
    name: 'Hereditary Angioedema',
    synonyms: ['HAE', 'hereditary angioedema', 'C1-INH deficiency', 'HAE type I', 'HAE type II', 'bradykinin-mediated angioedema'],
    icd10_codes: ['D84.1'],
    therapy_area: 'rare_disease',
    us_prevalence: 8000,
    us_incidence: 400,
    prevalence_source: 'US Hereditary Angioedema Association 2024; HAEA',
    diagnosis_rate: 0.70,
    treatment_rate: 0.85,
    cagr_5yr: 8.5,
    major_competitors: [
      'Takhzyro (lanadelumab, Takeda) — anti-kallikrein mAb prophylaxis',
      'Haegarda (SC C1-INH, CSL Behring) — prophylaxis',
      'Orladeyo (berotralstat, BioCryst) — oral kallikrein inhibitor prophylaxis',
      'Firazyr (icatibant, Takeda) — bradykinin B2 receptor antagonist acute',
      'Cinryze (C1-INH IV, Takeda)',
      'Kalbitor (ecallantide, Takeda)',
    ],
    market_growth_driver: 'Oral prophylaxis expansion, FXII-targeted therapies, gene therapy/editing approaches, attack-free status as treatment goal',
    therapy_area_pricing_context: 'Takhzyro at $480K+ annually; Orladeyo oral at $400K+. Ultra-rare; strong orphan pricing environment.',
  },

  {
    name: 'Phenylketonuria',
    synonyms: ['PKU', 'phenylketonuria', 'PAH deficiency', 'phenylalanine hydroxylase deficiency', 'hyperphenylalaninemia'],
    icd10_codes: ['E70.0', 'E70.1'],
    therapy_area: 'rare_disease',
    us_prevalence: 16500,
    us_incidence: 350,
    prevalence_source: 'National PKU Alliance 2024; NPKUA; newborn screening data',
    diagnosis_rate: 0.98,
    treatment_rate: 0.75,
    cagr_5yr: 12.0,
    major_competitors: [
      'Palynziq (pegvaliase, BioMarin) — enzyme substitution',
      'Kuvan (sapropterin, BioMarin) — BH4 cofactor (responsive patients)',
      'Dietary phenylalanine restriction (medical food)',
    ],
    market_growth_driver: 'Gene therapy approaches (BioMarin AAV), mRNA therapy, enzyme replacement improvements, adherence to diet declining in adults creating treatment need',
    therapy_area_pricing_context: 'Palynziq at $200K+ annually; Kuvan at $100K+. Gene therapy could command $1M-$2M one-time.',
  },

  {
    name: 'Wilson Disease',
    synonyms: ['Wilson disease', 'hepatolenticular degeneration', 'WD', 'copper storage disease'],
    icd10_codes: ['E83.01'],
    therapy_area: 'rare_disease',
    us_prevalence: 9000,
    us_incidence: 500,
    prevalence_source: 'Wilson Disease Association 2024; published epidemiology',
    diagnosis_rate: 0.55,
    treatment_rate: 0.80,
    cagr_5yr: 10.0,
    major_competitors: [
      'Penicillamine (generic) — chelation',
      'Trientine (generic) — chelation',
      'Zinc acetate (generic) — maintenance',
      'Chelator combinations (off-label)',
    ],
    market_growth_driver: 'Underdiagnosis, novel chelation agents with improved safety profile, gene therapy approaches, bis-choline tetrathiomolybdate (Alexion) development',
    therapy_area_pricing_context: 'Current generics are inexpensive; branded novel chelator could command $100K-$200K annually. Gene therapy $1M+.',
  },

  {
    name: 'Lysosomal Acid Lipase Deficiency',
    synonyms: ['LAL-D', 'LAL deficiency', 'Wolman disease', 'cholesteryl ester storage disease', 'CESD'],
    icd10_codes: ['E75.5'],
    therapy_area: 'rare_disease',
    us_prevalence: 2500,
    us_incidence: 100,
    prevalence_source: 'Published epidemiology 2024; LAL-D Foundation; newborn screening estimates',
    diagnosis_rate: 0.30,
    treatment_rate: 0.75,
    cagr_5yr: 12.0,
    major_competitors: [
      'Kanuma (sebelipase alfa, Alexion) — ERT',
    ],
    market_growth_driver: 'Severe underdiagnosis, newborn screening potential, gene therapy approaches, combination with lipid-lowering agents',
    therapy_area_pricing_context: 'Kanuma at $350K-$600K annually (weight-based dosing). Ultra-rare; orphan drug pricing with minimal competition.',
  },

  {
    name: 'Acute Hepatic Porphyria',
    synonyms: ['AHP', 'acute intermittent porphyria', 'AIP', 'porphyria', 'hepatic porphyria'],
    icd10_codes: ['E80.20', 'E80.21'],
    therapy_area: 'rare_disease',
    us_prevalence: 8000,
    us_incidence: 500,
    prevalence_source: 'American Porphyria Foundation 2024; published epidemiology',
    diagnosis_rate: 0.40,
    treatment_rate: 0.70,
    cagr_5yr: 10.0,
    major_competitors: [
      'Givlaari (givosiran, Alnylam) — RNAi targeting ALAS1',
      'Panhematin (hemin, Recordati) — acute attacks',
    ],
    market_growth_driver: 'RNAi therapy reducing attacks, underdiagnosis improvement, gene therapy approaches, broader porphyria subtype coverage',
    therapy_area_pricing_context: 'Givlaari at $575K annually. Ultra-rare; established orphan premium pricing.',
  },

  {
    name: 'Hemophilia A',
    synonyms: ['hemophilia A', 'factor VIII deficiency', 'FVIII deficiency', 'classic hemophilia', 'HA'],
    icd10_codes: ['D66'],
    therapy_area: 'rare_disease',
    us_prevalence: 20000,
    us_incidence: 400,
    prevalence_source: 'National Hemophilia Foundation 2024; CDC UDC data',
    diagnosis_rate: 0.95,
    treatment_rate: 0.92,
    cagr_5yr: 8.0,
    major_competitors: [
      'Hemlibra (emicizumab, Roche) — bispecific mAb',
      'Roctavian (valoctocogene roxaparvovec, BioMarin) — gene therapy',
      'Eloctate (efmoroctocog alfa, Sanofi)',
      'Advate (octocog alfa, Takeda)',
      'Adynovate (rurioctocog alfa pegol, Takeda)',
      'Esperoct (turoctocog alfa pegol, Novo Nordisk)',
    ],
    market_growth_driver: 'Gene therapy competition, Hemlibra subcutaneous prophylaxis dominance, next-gen gene therapies, non-factor replacement approaches',
    therapy_area_pricing_context: 'Factor replacement $200K-$500K annually; Hemlibra $500K+; Roctavian gene therapy $2.9M one-time.',
  },

  {
    name: 'Hemophilia B',
    synonyms: ['hemophilia B', 'factor IX deficiency', 'FIX deficiency', 'Christmas disease', 'HB'],
    icd10_codes: ['D67'],
    therapy_area: 'rare_disease',
    us_prevalence: 6000,
    us_incidence: 100,
    prevalence_source: 'National Hemophilia Foundation 2024; CDC UDC data',
    diagnosis_rate: 0.95,
    treatment_rate: 0.92,
    cagr_5yr: 12.0,
    major_competitors: [
      'Hemgenix (etranacogene dezaparvovec, CSL Behring) — gene therapy ($3.5M)',
      'BeneFIX (nonacog alfa, Pfizer)',
      'Alprolix (eftrenonacog alfa, Sanofi)',
      'Idelvion (albutrepenonacog alfa, CSL Behring)',
      'Rebinyn (nonacog beta pegol, Novo Nordisk)',
      'Fitusiran (alhemo, Sanofi) — anti-AT inhibitor',
    ],
    market_growth_driver: 'Gene therapy at $3.5M sets pricing benchmark, fitusiran subcutaneous prophylaxis, next-gen gene therapy with improved durability',
    therapy_area_pricing_context: 'Hemgenix at $3.5M (most expensive drug ever). Factor replacement $200K-$400K annually. Gene therapy curative potential justifies one-time premium.',
  },

  {
    name: 'Hunter Syndrome',
    synonyms: ['MPS II', 'mucopolysaccharidosis type II', 'Hunter syndrome', 'iduronate-2-sulfatase deficiency'],
    icd10_codes: ['E76.1'],
    therapy_area: 'rare_disease',
    us_prevalence: 2000,
    us_incidence: 100,
    prevalence_source: 'National MPS Society 2024; published epidemiology',
    diagnosis_rate: 0.85,
    treatment_rate: 0.80,
    cagr_5yr: 8.0,
    major_competitors: [
      'Elaprase (idursulfase, Takeda) — ERT',
      'Hunterase (idursulfase beta, GC Pharma) — ERT',
    ],
    market_growth_driver: 'CNS-penetrant ERT, intrathecal enzyme delivery, gene therapy, BBB-penetrant approaches for neuronopathic form',
    therapy_area_pricing_context: 'Elaprase at $375K-$750K annually (weight-based). Ultra-rare; orphan pricing with limited competition.',
  },

  {
    name: 'Hurler Syndrome',
    synonyms: ['MPS I', 'mucopolysaccharidosis type I', 'Hurler syndrome', 'Scheie syndrome', 'Hurler-Scheie', 'alpha-L-iduronidase deficiency'],
    icd10_codes: ['E76.01', 'E76.02', 'E76.03'],
    therapy_area: 'rare_disease',
    us_prevalence: 1500,
    us_incidence: 80,
    prevalence_source: 'National MPS Society 2024; published epidemiology',
    diagnosis_rate: 0.88,
    treatment_rate: 0.85,
    cagr_5yr: 9.0,
    major_competitors: [
      'Aldurazyme (laronidase, Sanofi) — ERT',
      'HSCT (hematopoietic stem cell transplant) — severe form',
    ],
    market_growth_driver: 'Gene therapy approaches, CNS-directed therapy, improved newborn screening, combination ERT+HSCT strategies',
    therapy_area_pricing_context: 'Aldurazyme at $200K-$500K annually. Ultra-rare; orphan pricing. Gene therapy could command $2M+.',
  },

  {
    name: 'Niemann-Pick Disease Type C',
    synonyms: ['NPC', 'Niemann-Pick type C', 'NPC1', 'NPC2', 'Niemann-Pick C'],
    icd10_codes: ['E75.242'],
    therapy_area: 'rare_disease',
    us_prevalence: 1500,
    us_incidence: 100,
    prevalence_source: 'National Niemann-Pick Disease Foundation 2024; published epidemiology',
    diagnosis_rate: 0.50,
    treatment_rate: 0.65,
    cagr_5yr: 15.0,
    major_competitors: [
      'Miglustat (generic) — substrate reduction (off-label in US, approved in EU)',
      'Arimoclomol — recently rejected by FDA',
      'Cyclodextrin (investigational)',
    ],
    market_growth_driver: 'No FDA-approved disease-specific therapy, gene therapy approaches, cyclodextrin development, improved diagnosis via biomarkers',
    therapy_area_pricing_context: 'Ultra-rare neurodegenerative; first approved therapy could command $300K-$500K annually.',
  },

  {
    name: 'Batten Disease',
    synonyms: ['CLN', 'neuronal ceroid lipofuscinosis', 'NCL', 'Batten disease', 'CLN2', 'CLN3', 'CLN6'],
    icd10_codes: ['E75.4'],
    therapy_area: 'rare_disease',
    us_prevalence: 2500,
    us_incidence: 200,
    prevalence_source: 'Batten Disease Support and Research Association 2024; published epidemiology',
    diagnosis_rate: 0.75,
    treatment_rate: 0.70,
    cagr_5yr: 18.0,
    major_competitors: [
      'Brineura (cerliponase alfa, BioMarin) — intracerebroventricular ERT for CLN2',
    ],
    market_growth_driver: 'Gene therapy for multiple CLN subtypes, improved newborn screening, Brineura precedent for CNS enzyme delivery, AAV gene therapy trials active',
    therapy_area_pricing_context: 'Brineura at $730K annually with intracerebroventricular delivery. Ultra-rare pediatric; gene therapy $2M-$3M one-time.',
  },

  {
    name: 'Epidermolysis Bullosa',
    synonyms: ['EB', 'epidermolysis bullosa', 'butterfly disease', 'dystrophic EB', 'junctional EB', 'EB simplex'],
    icd10_codes: ['Q81.0', 'Q81.1', 'Q81.2', 'Q81.8', 'Q81.9'],
    therapy_area: 'rare_disease',
    us_prevalence: 25000,
    us_incidence: 1000,
    prevalence_source: 'EB Research Partnership 2024; debra of America; published epidemiology',
    diagnosis_rate: 0.90,
    treatment_rate: 0.70,
    cagr_5yr: 22.0,
    major_competitors: [
      'Vyjuvek (beremagene geperpavec, Krystal Biotech) — topical gene therapy for DEB',
      'Wound care management (standard of care)',
      'Filsuvez (birch bark extract, Amryt) — approved in EU',
    ],
    market_growth_driver: 'Vyjuvek gene therapy approval breakthrough, systemic gene therapy, protein replacement, cell therapy, wound healing approaches for multiple EB subtypes',
    therapy_area_pricing_context: 'Vyjuvek at $24K per vial (chronic use). Ultra-rare with high treatment burden; innovative therapies command orphan premium.',
  },

  {
    name: 'Achondroplasia',
    synonyms: ['achondroplasia', 'ACH', 'FGFR3-related dwarfism', 'short-limbed dwarfism'],
    icd10_codes: ['Q77.4'],
    therapy_area: 'rare_disease',
    us_prevalence: 28000,
    us_incidence: 800,
    prevalence_source: 'Little People of America 2024; published epidemiology estimates',
    diagnosis_rate: 0.95,
    treatment_rate: 0.40,
    cagr_5yr: 25.0,
    major_competitors: [
      'Voxzogo (vosoritide, BioMarin) — CNP analog, first approved for achondroplasia',
      'Growth hormone (off-label)',
      'Surgical limb lengthening',
    ],
    market_growth_driver: 'Voxzogo approval precedent, long-term growth data accumulating, infant formulation development, combination approaches, adult indications',
    therapy_area_pricing_context: 'Voxzogo at $325K annually (pediatric). Rare genetic condition; orphan drug pricing with strong payer acceptance.',
  },

  {
    name: 'Hypophosphatasia',
    synonyms: ['HPP', 'hypophosphatasia', 'TNSALP deficiency', 'phosphoethanolaminuria'],
    icd10_codes: ['E83.30', 'E83.39'],
    therapy_area: 'rare_disease',
    us_prevalence: 4000,
    us_incidence: 200,
    prevalence_source: 'Soft Bones Foundation 2024; published epidemiology estimates',
    diagnosis_rate: 0.50,
    treatment_rate: 0.75,
    cagr_5yr: 10.0,
    major_competitors: [
      'Strensiq (asfotase alfa, Alexion) — ERT',
    ],
    market_growth_driver: 'Underdiagnosis, expanded indications for adult-onset HPP, gene therapy potential, next-gen enzyme replacement',
    therapy_area_pricing_context: 'Strensiq at $250K-$800K annually (weight-based). Ultra-rare; orphan pricing benchmark.',
  },

  {
    name: 'Alpha-1 Antitrypsin Deficiency',
    synonyms: ['AATD', 'alpha-1', 'A1AT deficiency', 'AAT deficiency', 'alpha-1 antitrypsin deficiency'],
    icd10_codes: ['E88.01'],
    therapy_area: 'rare_disease',
    us_prevalence: 100000,
    us_incidence: 3000,
    prevalence_source: 'Alpha-1 Foundation 2024; published epidemiology (estimated ~100K, most undiagnosed)',
    diagnosis_rate: 0.10,
    treatment_rate: 0.50,
    cagr_5yr: 8.5,
    major_competitors: [
      'Prolastin-C (alpha-1 proteinase inhibitor, Grifols) — augmentation',
      'Aralast NP (alpha-1 proteinase inhibitor, Takeda)',
      'Zemaira (alpha-1 proteinase inhibitor, CSL Behring)',
      'Glassia (alpha-1 proteinase inhibitor, Takeda)',
    ],
    market_growth_driver: 'Massive underdiagnosis (only ~10% diagnosed), gene therapy approaches, next-gen augmentation therapy, RNA-based liver-targeted therapies',
    therapy_area_pricing_context: 'Augmentation therapy at $80K-$120K annually. Large undiagnosed population; gene therapy could command $1M+ one-time.',
  },

  {
    name: 'Prader-Willi Syndrome',
    synonyms: ['PWS', 'Prader-Willi syndrome', 'Prader-Willi', '15q11-q13 deletion syndrome'],
    icd10_codes: ['Q87.11'],
    therapy_area: 'rare_disease',
    us_prevalence: 20000,
    us_incidence: 600,
    prevalence_source: 'Prader-Willi Syndrome Association 2024; published epidemiology',
    diagnosis_rate: 0.90,
    treatment_rate: 0.65,
    cagr_5yr: 15.0,
    major_competitors: [
      'Growth hormone (Genotropin, Norditropin, etc.) — for growth/body composition',
      'No FDA-approved therapy for hyperphagia (core symptom)',
    ],
    market_growth_driver: 'Hyperphagia-targeting therapies in development (DCCR, setmelanotide, carbetocin), oxytocin approaches, no approved treatment for core symptom',
    therapy_area_pricing_context: 'GH at $30K-$60K annually; first approved hyperphagia agent could command $100K-$300K annually. Orphan pricing applicable.',
  },

  {
    name: 'Tuberous Sclerosis Complex',
    synonyms: ['TSC', 'tuberous sclerosis', 'tuberous sclerosis complex', 'Bourneville disease'],
    icd10_codes: ['Q85.1'],
    therapy_area: 'rare_disease',
    us_prevalence: 50000,
    us_incidence: 2000,
    prevalence_source: 'TSC Alliance 2024; published epidemiology estimates',
    diagnosis_rate: 0.80,
    treatment_rate: 0.70,
    cagr_5yr: 9.0,
    major_competitors: [
      'Afinitor (everolimus, Novartis) — mTOR inhibitor for SEGA, renal AML',
      'Hyftor (topical rapamycin, Nobelpharma) — facial angiofibromas',
      'Epidiolex (cannabidiol, Jazz Pharma) — TSC-associated seizures',
      'Vigabatrin (Lundbeck) — infantile spasms in TSC',
    ],
    market_growth_driver: 'Comprehensive multi-organ approach, mTOR inhibitor expanded indications, gene therapy targeting TSC1/TSC2, infantile spasm prevention',
    therapy_area_pricing_context: 'Afinitor at $150K+ annually; Epidiolex at $32K. Multi-organ disease requiring chronic management supports sustained pricing.',
  },

  {
    name: 'Spinal and Bulbar Muscular Atrophy',
    synonyms: ['SBMA', 'Kennedy disease', "Kennedy's disease", 'X-linked spinal and bulbar muscular atrophy'],
    icd10_codes: ['G12.1'],
    therapy_area: 'rare_disease',
    us_prevalence: 3000,
    us_incidence: 200,
    prevalence_source: 'Kennedy Disease Association 2024; published epidemiology',
    diagnosis_rate: 0.60,
    treatment_rate: 0.30,
    cagr_5yr: 15.0,
    major_competitors: [
      'No FDA-approved therapies',
      'Physical therapy (standard of care)',
      'Testosterone supplementation (off-label)',
    ],
    market_growth_driver: 'ASO targeting polyglutamine expansion, gene silencing approaches, androgen receptor modulation, complete treatment void creates opportunity',
    therapy_area_pricing_context: 'Ultra-rare; first disease-modifying therapy could command $200K-$500K annually. Orphan drug designation available.',
  },

  {
    name: 'Homozygous Familial Hypercholesterolemia',
    synonyms: ['HoFH', 'homozygous FH', 'homozygous familial hypercholesterolemia'],
    icd10_codes: ['E78.01'],
    therapy_area: 'rare_disease',
    us_prevalence: 1300,
    us_incidence: 60,
    prevalence_source: 'FH Foundation 2024; published epidemiology (1:300K-1:160K prevalence)',
    diagnosis_rate: 0.80,
    treatment_rate: 0.90,
    cagr_5yr: 8.0,
    major_competitors: [
      'Juxtapid (lomitapide, Amryt) — MTP inhibitor',
      'Evkeeza (evinacumab, Regeneron) — anti-ANGPTL3',
      'Repatha (evolocumab, Amgen) — PCSK9 mAb',
      'LDL apheresis',
    ],
    market_growth_driver: 'ANGPTL3 inhibition, gene therapy approaches, siRNA targeting HoFH, combination lipid-lowering strategies, LDL apheresis reduction',
    therapy_area_pricing_context: 'Evkeeza at $450K annually; Juxtapid at $350K. Ultra-rare with severe cardiovascular risk; orphan premium pricing.',
  },

  {
    name: 'Congenital Adrenal Hyperplasia',
    synonyms: ['CAH', 'congenital adrenal hyperplasia', '21-hydroxylase deficiency', 'classic CAH', 'nonclassic CAH'],
    icd10_codes: ['E25.0'],
    therapy_area: 'rare_disease',
    us_prevalence: 25000,
    us_incidence: 800,
    prevalence_source: 'CARES Foundation 2024; published newborn screening data',
    diagnosis_rate: 0.90,
    treatment_rate: 0.85,
    cagr_5yr: 12.0,
    major_competitors: [
      'Hydrocortisone (generic)',
      'Fludrocortisone (generic)',
      'Crinecerfont (Neurocrine Biosciences) — CRF1 antagonist, Phase 3',
      'Tildacerfont (Spruce Biosciences) — CRF1 antagonist',
    ],
    market_growth_driver: 'CRF1 receptor antagonists enabling physiologic cortisol replacement, gene therapy potential, improved newborn screening, adult disease management',
    therapy_area_pricing_context: 'Generic glucocorticoids very inexpensive; novel CRF1 antagonists could command $100K-$200K annually. Orphan pricing applicable.',
  },

  {
    name: 'Aromatic L-Amino Acid Decarboxylase Deficiency',
    synonyms: ['AADC deficiency', 'AADCD', 'aromatic L-amino acid decarboxylase deficiency', 'dopa decarboxylase deficiency'],
    icd10_codes: ['E70.8'],
    therapy_area: 'rare_disease',
    us_prevalence: 300,
    us_incidence: 20,
    prevalence_source: 'Published literature 2024; AADC Research Trust',
    diagnosis_rate: 0.50,
    treatment_rate: 0.70,
    cagr_5yr: 25.0,
    major_competitors: [
      'Upstaza (eladocagene exuparvovec, PTC Therapeutics) — gene therapy (EU approved)',
      'Dopamine agonists (off-label)',
      'MAO inhibitors (off-label)',
    ],
    market_growth_driver: 'Gene therapy approval precedent in EU, FDA pathway in progress, ultra-rare with transformative treatment potential, newborn screening possible',
    therapy_area_pricing_context: 'Ultra-rare gene therapy; Upstaza priced at $3.5M in EU. US approval could command similar pricing.',
  },

  // ──────────────────────────────────────────
  // IMMUNOLOGY / INFLAMMATION
  // ──────────────────────────────────────────
  {
    name: 'Rheumatoid Arthritis',
    synonyms: ['RA', 'rheumatoid arthritis', 'seronegative RA', 'seropositive RA'],
    icd10_codes: ['M05', 'M06'],
    therapy_area: 'immunology',
    us_prevalence: 1500000,
    us_incidence: 75000,
    prevalence_source: 'American College of Rheumatology 2024; ACR Epidemiology',
    diagnosis_rate: 0.72,
    treatment_rate: 0.75,
    cagr_5yr: 5.2,
    major_competitors: [
      'Humira (adalimumab, AbbVie)',
      'Rinvoq (upadacitinib, AbbVie)',
      'Skyrizi (risankizumab, AbbVie)',
      'Orencia (abatacept, BMS)',
      'Actemra (tocilizumab, Roche)',
      'Xeljanz (tofacitinib, Pfizer)',
    ],
    market_growth_driver: 'Post-Humira biosimilar dynamics, next-gen selective JAKi, B cell depletion, bispecifics',
    therapy_area_pricing_context: 'Highly competitive; TNF biosimilars driving price pressure. Novel mechanisms with superior efficacy needed for premium positioning ($40K-$60K annually)',
  },

  {
    name: 'Systemic Lupus Erythematosus',
    synonyms: ['SLE', 'lupus', 'systemic lupus', 'lupus erythematosus'],
    icd10_codes: ['M32.0', 'M32.1', 'M32.10', 'M32.11', 'M32.12', 'M32.9'],
    therapy_area: 'immunology',
    us_prevalence: 300000,
    us_incidence: 16000,
    prevalence_source: 'Lupus Foundation of America 2024; CDC epidemiology estimates',
    diagnosis_rate: 0.65,
    treatment_rate: 0.75,
    cagr_5yr: 10.5,
    major_competitors: [
      'Benlysta (belimumab, GSK) — anti-BLyS',
      'Saphnelo (anifrolumab, AstraZeneca) — anti-IFNAR1',
      'Hydroxychloroquine (generic)',
      'Mycophenolate (generic)',
      'Rituximab (off-label)',
    ],
    market_growth_driver: 'Anti-IFNAR pathway expansion, complement inhibitors for lupus nephritis, CAR-T for refractory disease, large underserved population',
    therapy_area_pricing_context: 'Benlysta at $35K annually; Saphnelo at $45K. Novel biologics with superior efficacy could command $50K-$80K. Health disparities in prevalence.',
  },

  {
    name: 'Psoriatic Arthritis',
    synonyms: ['PsA', 'psoriatic arthritis', 'arthritis psoriatic', 'psoriatic spondyloarthritis'],
    icd10_codes: ['L40.50', 'L40.51', 'L40.52', 'L40.53', 'L40.59'],
    therapy_area: 'immunology',
    us_prevalence: 1200000,
    us_incidence: 60000,
    prevalence_source: 'National Psoriasis Foundation 2024; ACR epidemiology estimates',
    diagnosis_rate: 0.60,
    treatment_rate: 0.70,
    cagr_5yr: 7.8,
    major_competitors: [
      'Cosentyx (secukinumab, Novartis) — anti-IL-17A',
      'Taltz (ixekizumab, Eli Lilly) — anti-IL-17A',
      'Skyrizi (risankizumab, AbbVie) — anti-IL-23',
      'Tremfya (guselkumab, Janssen) — anti-IL-23',
      'Rinvoq (upadacitinib, AbbVie) — JAK inhibitor',
      'Otezla (apremilast, Amgen) — PDE4 inhibitor',
      'Humira/biosimilars (adalimumab)',
    ],
    market_growth_driver: 'IL-23 class growing share, dual-domain disease management (joints+skin), bispecific IL-17A/F antibodies, earlier biologic intervention',
    therapy_area_pricing_context: 'IL-17/IL-23 biologics at $60K-$80K annually. Biosimilar TNF pressure driving novel mechanism adoption. Oral agents at $30K-$40K.',
  },

  {
    name: 'Ankylosing Spondylitis',
    synonyms: ['AS', 'ankylosing spondylitis', 'axial spondyloarthritis', 'axSpA', 'radiographic axSpA', 'non-radiographic axSpA', 'nr-axSpA'],
    icd10_codes: ['M45.0', 'M45.1', 'M45.2', 'M45.9'],
    therapy_area: 'immunology',
    us_prevalence: 600000,
    us_incidence: 30000,
    prevalence_source: 'Spondylitis Association of America 2024; published epidemiology',
    diagnosis_rate: 0.55,
    treatment_rate: 0.65,
    cagr_5yr: 7.0,
    major_competitors: [
      'Cosentyx (secukinumab, Novartis)',
      'Taltz (ixekizumab, Eli Lilly)',
      'Rinvoq (upadacitinib, AbbVie)',
      'Humira/biosimilars (adalimumab)',
      'NSAIDs (generic first-line)',
    ],
    market_growth_driver: 'IL-17 class dominance in axSpA, non-radiographic axSpA label expansion, JAK inhibitors providing oral option, earlier diagnosis via MRI',
    therapy_area_pricing_context: 'Biologics at $60K-$80K annually. Significant diagnosis delay (avg 7-10 years) creates untreated population opportunity.',
  },

  {
    name: 'Atopic Dermatitis',
    synonyms: ['AD', 'atopic dermatitis', 'eczema', 'atopic eczema', 'moderate-to-severe atopic dermatitis'],
    icd10_codes: ['L20.0', 'L20.81', 'L20.82', 'L20.84', 'L20.89', 'L20.9'],
    therapy_area: 'immunology',
    us_prevalence: 7900000,
    us_incidence: 800000,
    prevalence_source: 'National Eczema Association 2024; AAD epidemiology data',
    diagnosis_rate: 0.70,
    treatment_rate: 0.60,
    cagr_5yr: 14.0,
    major_competitors: [
      'Dupixent (dupilumab, Sanofi/Regeneron) — anti-IL-4Ra',
      'Rinvoq (upadacitinib, AbbVie) — JAK inhibitor',
      'Cibinqo (abrocitinib, Pfizer) — JAK inhibitor',
      'Adbry (tralokinumab, LEO Pharma) — anti-IL-13',
      'Opzelura (ruxolitinib cream, Incyte) — topical JAK inhibitor',
      'Eucrisa (crisaborole, Pfizer) — PDE4 topical',
    ],
    market_growth_driver: 'Dupixent blockbuster growth, JAK inhibitor oral option, OX40 ligand and TSLP targeting, pediatric age expansions, biologic penetration of moderate AD',
    therapy_area_pricing_context: 'Dupixent at $36K annually; JAK inhibitors at $50K-$65K. Massive addressable population drives very large market.',
  },

  {
    name: 'Plaque Psoriasis',
    synonyms: ['psoriasis', 'plaque psoriasis', 'PsO', 'chronic plaque psoriasis', 'moderate-to-severe psoriasis'],
    icd10_codes: ['L40.0', 'L40.1', 'L40.4', 'L40.8', 'L40.9'],
    therapy_area: 'immunology',
    us_prevalence: 3300000,
    us_incidence: 150000,
    prevalence_source: 'National Psoriasis Foundation 2024; AAD epidemiology data',
    diagnosis_rate: 0.80,
    treatment_rate: 0.65,
    cagr_5yr: 8.5,
    major_competitors: [
      'Skyrizi (risankizumab, AbbVie) — anti-IL-23',
      'Tremfya (guselkumab, Janssen) — anti-IL-23',
      'Cosentyx (secukinumab, Novartis) — anti-IL-17A',
      'Taltz (ixekizumab, Eli Lilly) — anti-IL-17A',
      'Bimzelx (bimekizumab, UCB) — anti-IL-17A/F',
      'Sotyktu (deucravacitinib, BMS) — TYK2 inhibitor oral',
      'Humira/biosimilars (adalimumab)',
    ],
    market_growth_driver: 'IL-23 class dominance, TYK2 selective inhibitors, high PASI 100 clearance rates as new standard, oral options expanding access',
    therapy_area_pricing_context: 'IL-23 biologics at $60K-$80K annually; TYK2 oral at $35K-$40K. Large market; competition driving differentiation on clearance rates.',
  },

  {
    name: "Crohn's Disease",
    synonyms: ["Crohn's", 'CD', "Crohn's disease", 'Crohn disease', 'regional enteritis', 'ileitis'],
    icd10_codes: ['K50.0', 'K50.1', 'K50.8', 'K50.9'],
    therapy_area: 'immunology',
    us_prevalence: 780000,
    us_incidence: 33000,
    prevalence_source: "Crohn's and Colitis Foundation 2024; CDC GI health estimates",
    diagnosis_rate: 0.78,
    treatment_rate: 0.80,
    cagr_5yr: 8.2,
    major_competitors: [
      'Skyrizi (risankizumab, AbbVie) — anti-IL-23',
      'Entyvio (vedolizumab, Takeda) — anti-integrin',
      'Stelara (ustekinumab, Janssen) — anti-IL-12/23',
      'Rinvoq (upadacitinib, AbbVie) — JAK inhibitor',
      'Humira/biosimilars (adalimumab)',
      'Remicade/biosimilars (infliximab)',
    ],
    market_growth_driver: 'IL-23 class gaining 1L share, JAK inhibitor oral option, S1P modulators, anti-TL1A agents in Phase 3 (tulisokibart), combination biologics',
    therapy_area_pricing_context: 'Biologics at $50K-$80K annually. Biosimilar TNF creating headroom for novel mechanisms. Anti-TL1A could be next major class.',
  },

  {
    name: 'Ulcerative Colitis',
    synonyms: ['UC', 'ulcerative colitis', 'ulcerative proctitis', 'pancolitis', 'left-sided colitis'],
    icd10_codes: ['K51.0', 'K51.2', 'K51.3', 'K51.5', 'K51.8', 'K51.9'],
    therapy_area: 'immunology',
    us_prevalence: 900000,
    us_incidence: 38000,
    prevalence_source: "Crohn's and Colitis Foundation 2024; CDC GI health estimates",
    diagnosis_rate: 0.80,
    treatment_rate: 0.82,
    cagr_5yr: 8.5,
    major_competitors: [
      'Entyvio (vedolizumab, Takeda)',
      'Zeposia (ozanimod, BMS) — S1P modulator oral',
      'Rinvoq (upadacitinib, AbbVie) — JAK inhibitor',
      'Xeljanz (tofacitinib, Pfizer) — JAK inhibitor',
      'Humira/biosimilars (adalimumab)',
      'Remicade/biosimilars (infliximab)',
      'Omvoh (mirikizumab, Eli Lilly) — anti-IL-23',
    ],
    market_growth_driver: 'S1P modulators oral convenience, anti-IL-23 expansion, anti-TL1A agents, biologic penetration growth, colectomy prevention strategies',
    therapy_area_pricing_context: 'Biologics at $50K-$80K annually; oral agents at $40K-$60K. Large and growing IBD market.',
  },

  {
    name: 'Giant Cell Arteritis',
    synonyms: ['GCA', 'giant cell arteritis', 'temporal arteritis', 'cranial arteritis', 'Horton disease'],
    icd10_codes: ['M31.5', 'M31.6'],
    therapy_area: 'immunology',
    us_prevalence: 80000,
    us_incidence: 20000,
    prevalence_source: 'Vasculitis Foundation 2024; published epidemiology estimates',
    diagnosis_rate: 0.70,
    treatment_rate: 0.85,
    cagr_5yr: 12.0,
    major_competitors: [
      'Actemra (tocilizumab, Roche) — anti-IL-6R, first approved for GCA',
      'Prednisone (generic) — standard of care',
      'Methotrexate (generic, off-label)',
    ],
    market_growth_driver: 'Actemra monotherapy enabling steroid sparing, novel targets (GM-CSF, CD20), unmet need in relapsing disease, imaging-based diagnosis improvement',
    therapy_area_pricing_context: 'Actemra at $24K-$36K annually. Steroid-sparing agents valued by payers. Novel mechanisms could command $40K-$60K.',
  },

  {
    name: 'Alopecia Areata',
    synonyms: ['AA', 'alopecia areata', 'alopecia totalis', 'alopecia universalis', 'patchy hair loss'],
    icd10_codes: ['L63.0', 'L63.1', 'L63.2', 'L63.8', 'L63.9'],
    therapy_area: 'immunology',
    us_prevalence: 700000,
    us_incidence: 200000,
    prevalence_source: 'National Alopecia Areata Foundation 2024; NAAF; published epidemiology',
    diagnosis_rate: 0.75,
    treatment_rate: 0.50,
    cagr_5yr: 22.0,
    major_competitors: [
      'Olumiant (baricitinib, Eli Lilly) — JAK inhibitor, first FDA-approved for AA',
      'Litfulo (ritlecitinib, Pfizer) — JAK3/TEC inhibitor',
      'Corticosteroids (generic, intralesional)',
    ],
    market_growth_driver: 'First-ever FDA approvals in 2022-2023, JAK inhibitor class expansion, large undertreated population, topical JAK inhibitors in development',
    therapy_area_pricing_context: 'Olumiant at $55K annually; Litfulo at $49K. Large market opportunity with recent class creation.',
  },

  {
    name: 'Vitiligo',
    synonyms: ['vitiligo', 'nonsegmental vitiligo', 'segmental vitiligo', 'leukoderma'],
    icd10_codes: ['L80'],
    therapy_area: 'immunology',
    us_prevalence: 2500000,
    us_incidence: 200000,
    prevalence_source: 'Global Vitiligo Foundation 2024; AAD epidemiology data',
    diagnosis_rate: 0.70,
    treatment_rate: 0.35,
    cagr_5yr: 18.0,
    major_competitors: [
      'Opzelura (ruxolitinib cream, Incyte) — topical JAK inhibitor, first FDA-approved for vitiligo',
      'Phototherapy (NB-UVB)',
      'Topical corticosteroids (generic)',
      'Topical calcineurin inhibitors (generic)',
    ],
    market_growth_driver: 'Opzelura first-ever FDA approval, massive undertreated population, oral JAK inhibitors in development, combination topical+phototherapy optimization',
    therapy_area_pricing_context: 'Opzelura at $24K annually. Large addressable market with very low current treatment rates creates significant growth runway.',
  },

  {
    name: 'Eosinophilic Esophagitis',
    synonyms: ['EoE', 'eosinophilic esophagitis', 'allergic esophagitis', 'eosinophilic oesophagitis'],
    icd10_codes: ['K20.0'],
    therapy_area: 'immunology',
    us_prevalence: 160000,
    us_incidence: 20000,
    prevalence_source: 'American Partnership for Eosinophilic Disorders 2024; published epidemiology',
    diagnosis_rate: 0.55,
    treatment_rate: 0.65,
    cagr_5yr: 15.0,
    major_competitors: [
      'Dupixent (dupilumab, Sanofi/Regeneron) — anti-IL-4Ra, first FDA-approved biologic for EoE',
      'Proton pump inhibitors (generic)',
      'Swallowed topical corticosteroids (budesonide, fluticasone)',
      'Elimination diet',
    ],
    market_growth_driver: 'Dupixent first biologic approval, anti-IL-13 agents in development, massive underdiagnosis, rising prevalence, biologic penetration of allergic GI conditions',
    therapy_area_pricing_context: 'Dupixent at $36K annually. Growing diagnosed population. First-in-disease biologic sets pricing precedent for follow-on agents.',
  },

  {
    name: "Sjogren's Syndrome",
    synonyms: ["Sjogren's", 'Sjogren syndrome', 'primary Sjogren syndrome', 'SS', 'sicca syndrome'],
    icd10_codes: ['M35.00', 'M35.01', 'M35.02', 'M35.03', 'M35.09'],
    therapy_area: 'immunology',
    us_prevalence: 1000000,
    us_incidence: 40000,
    prevalence_source: "Sjogren's Foundation 2024; published epidemiology estimates",
    diagnosis_rate: 0.45,
    treatment_rate: 0.55,
    cagr_5yr: 12.0,
    major_competitors: [
      'No FDA-approved systemic therapies for primary Sjogren syndrome',
      'Pilocarpine (generic) — secretagogue',
      'Cevimeline (generic) — secretagogue',
      'Hydroxychloroquine (generic, off-label)',
      'Rituximab (off-label)',
    ],
    market_growth_driver: 'Complete treatment void for disease modification, anti-CD40 antibodies in development, BAFF/BLyS inhibition, IFN pathway targeting, large unmet need',
    therapy_area_pricing_context: 'No approved systemic therapy; first disease-modifying agent could command $40K-$80K annually. Large prevalent population.',
  },

  {
    name: 'Systemic Sclerosis',
    synonyms: ['SSc', 'scleroderma', 'systemic sclerosis', 'diffuse cutaneous systemic sclerosis', 'dcSSc', 'limited cutaneous SSc'],
    icd10_codes: ['M34.0', 'M34.1', 'M34.2', 'M34.81', 'M34.89', 'M34.9'],
    therapy_area: 'immunology',
    us_prevalence: 100000,
    us_incidence: 5000,
    prevalence_source: 'Scleroderma Foundation 2024; published epidemiology estimates',
    diagnosis_rate: 0.70,
    treatment_rate: 0.65,
    cagr_5yr: 10.0,
    major_competitors: [
      'Nintedanib (Boehringer, SSc-ILD)',
      'Mycophenolate (generic, off-label)',
      'Tocilizumab (Roche, off-label)',
      'Rituximab (off-label)',
      'Autologous HSCT (severe cases)',
    ],
    market_growth_driver: 'Anti-fibrotic agents for skin/lung disease, CD19-targeted therapies, CAR-T for refractory SSc, lysophosphatidic acid receptor antagonists',
    therapy_area_pricing_context: 'Limited approved options; novel disease-modifying agents could command $50K-$150K annually. Rare autoimmune disease with orphan potential.',
  },

  // ──────────────────────────────────────────
  // CARDIOLOGY
  // ──────────────────────────────────────────
  {
    name: 'Heart Failure with Reduced Ejection Fraction',
    synonyms: ['HFrEF', 'heart failure', 'systolic heart failure', 'CHF', 'congestive heart failure'],
    icd10_codes: ['I50.20', 'I50.21', 'I50.22', 'I50.23'],
    therapy_area: 'cardiovascular',
    us_prevalence: 3600000,
    us_incidence: 550000,
    prevalence_source: 'American Heart Association 2024 Statistical Update',
    diagnosis_rate: 0.80,
    treatment_rate: 0.70,
    cagr_5yr: 6.8,
    major_competitors: [
      'Entresto (sacubitril/valsartan, Novartis)',
      'Farxiga (dapagliflozin, AstraZeneca)',
      'Jardiance (empagliflozin, Boehringer)',
      'Verquvo (vericiguat, Merck/Bayer)',
      'Ivabradine (Amgen)',
      'ACE inhibitors / ARBs (generic)',
      'Beta blockers (generic)',
    ],
    market_growth_driver: 'SGLT2 class expansion, combination regimens, HFpEF emerging market, device-drug combination',
    therapy_area_pricing_context: 'Price-sensitive; generic backbone + branded agents. Novel mechanisms need strong outcome data for formulary positioning ($25K-$45K annually)',
  },

  {
    name: 'Heart Failure with Preserved Ejection Fraction',
    synonyms: ['HFpEF', 'diastolic heart failure', 'heart failure preserved EF', 'HF-PEF'],
    icd10_codes: ['I50.30', 'I50.31', 'I50.32', 'I50.33'],
    therapy_area: 'cardiovascular',
    us_prevalence: 3400000,
    us_incidence: 500000,
    prevalence_source: 'American Heart Association 2024 Statistical Update; EMPEROR-Preserved trial data',
    diagnosis_rate: 0.65,
    treatment_rate: 0.45,
    cagr_5yr: 12.0,
    major_competitors: [
      'Jardiance (empagliflozin, Boehringer) — first approved for HFpEF',
      'Farxiga (dapagliflozin, AstraZeneca)',
      'Entresto (sacubitril/valsartan, Novartis) — limited HFpEF data',
      'Diuretics (generic)',
      'MRAs (generic)',
    ],
    market_growth_driver: 'Massive undertreated population, SGLT2i as first approved class, novel targets (GLP-1 for obesity-HFpEF, titin modulators), phenotyping-driven precision medicine',
    therapy_area_pricing_context: 'SGLT2 inhibitors at $6K-$8K annually; novel mechanisms for HFpEF phenotypes could command $15K-$30K. Very large market opportunity.',
  },

  {
    name: 'Metabolic Dysfunction-Associated Steatohepatitis',
    synonyms: ['MASH', 'NASH', 'nonalcoholic steatohepatitis', 'metabolic steatohepatitis', 'fatty liver disease', 'MASLD'],
    icd10_codes: ['K75.81', 'K76.0'],
    therapy_area: 'cardiovascular',
    us_prevalence: 16500000,
    us_incidence: 2000000,
    prevalence_source: 'American Liver Foundation 2024; AASLD; published epidemiology',
    diagnosis_rate: 0.15,
    treatment_rate: 0.10,
    cagr_5yr: 35.0,
    major_competitors: [
      'Rezdiffra (resmetirom, Madrigal) — THR-beta agonist, first FDA-approved for NASH',
      'Semaglutide (Novo Nordisk) — GLP-1, Phase 3 for NASH',
      'Pioglitazone (generic, off-label)',
      'Vitamin E (supplement, off-label)',
    ],
    market_growth_driver: 'Rezdiffra first approval, GLP-1 class NASH data, massive underdiagnosed population, FXR agonists, combination approaches, non-invasive biomarker diagnosis expansion',
    therapy_area_pricing_context: 'Rezdiffra at $47K annually. Massive market potential (est. $25-40B at peak). GLP-1 repurposing could dominate.',
  },

  {
    name: 'Heterozygous Familial Hypercholesterolemia',
    synonyms: ['HeFH', 'familial hypercholesterolemia', 'FH', 'primary hypercholesterolemia', 'hyperlipidemia'],
    icd10_codes: ['E78.01', 'E78.00'],
    therapy_area: 'cardiovascular',
    us_prevalence: 1300000,
    us_incidence: 50000,
    prevalence_source: 'FH Foundation 2024; published epidemiology estimates',
    diagnosis_rate: 0.10,
    treatment_rate: 0.50,
    cagr_5yr: 10.0,
    major_competitors: [
      'Repatha (evolocumab, Amgen) — PCSK9 mAb',
      'Praluent (alirocumab, Regeneron/Sanofi) — PCSK9 mAb',
      'Leqvio (inclisiran, Novartis) — siRNA PCSK9',
      'Nexletol (bempedoic acid, Esperion)',
      'Statins (generic, first-line)',
      'Ezetimibe (generic)',
    ],
    market_growth_driver: 'PCSK9 siRNA once-yearly dosing, massive underdiagnosis (only ~10% diagnosed), cascade genetic screening, payer coverage expanding for PCSK9',
    therapy_area_pricing_context: 'PCSK9 mAbs at $5K-$6K annually (post-price cuts); Leqvio at $6.5K. Massive population if screening improves.',
  },

  {
    name: 'Pulmonary Arterial Hypertension',
    synonyms: ['PAH', 'pulmonary arterial hypertension', 'pulmonary hypertension', 'WHO Group 1 PH', 'IPAH'],
    icd10_codes: ['I27.0', 'I27.20', 'I27.21', 'I27.24'],
    therapy_area: 'cardiovascular',
    us_prevalence: 50000,
    us_incidence: 5000,
    prevalence_source: 'Pulmonary Hypertension Association 2024; REVEAL Registry',
    diagnosis_rate: 0.60,
    treatment_rate: 0.85,
    cagr_5yr: 8.5,
    major_competitors: [
      'Opsumit (macitentan, Janssen) — ERA',
      'Uptravi (selexipag, Janssen) — IP receptor agonist',
      'Adempas (riociguat, Bayer) — sGC stimulator',
      'Tyvaso/Tyvaso DPI (treprostinil, United Therapeutics) — prostacyclin',
      'Sildenafil (generic) — PDE5 inhibitor',
      'Ambrisentan (generic) — ERA',
      'Winrevair (sotatercept, MSD) — activin signaling inhibitor',
    ],
    market_growth_driver: 'Sotatercept (Winrevair) approval as potential best-in-class, triple combination therapy adoption, activin pathway paradigm shift, earlier diagnosis via screening',
    therapy_area_pricing_context: 'PAH therapies $50K-$200K annually; Winrevair at $250K+. Rare disease pricing with high treatment complexity.',
  },

  {
    name: 'Chronic Thromboembolic Pulmonary Hypertension',
    synonyms: ['CTEPH', 'chronic thromboembolic PH', 'thromboembolic pulmonary hypertension'],
    icd10_codes: ['I27.24'],
    therapy_area: 'cardiovascular',
    us_prevalence: 8000,
    us_incidence: 3000,
    prevalence_source: 'PH Association 2024; International CTEPH Association; published epidemiology',
    diagnosis_rate: 0.50,
    treatment_rate: 0.75,
    cagr_5yr: 9.0,
    major_competitors: [
      'Adempas (riociguat, Bayer) — only FDA-approved drug for CTEPH',
      'Pulmonary thromboendarterectomy (PTE surgery)',
      'Balloon pulmonary angioplasty (BPA)',
    ],
    market_growth_driver: 'Underdiagnosis, multimodal treatment (surgery+BPA+drugs), sotatercept expansion potential, better imaging diagnostics',
    therapy_area_pricing_context: 'Adempas at $100K annually; combination with surgical approaches. Rare PH subtype supports orphan pricing.',
  },

  {
    name: 'Peripheral Artery Disease',
    synonyms: ['PAD', 'peripheral artery disease', 'peripheral vascular disease', 'PVD', 'claudication', 'critical limb ischemia', 'CLI'],
    icd10_codes: ['I73.9', 'I70.20', 'I70.21', 'I70.22', 'I70.23', 'I70.24', 'I70.25'],
    therapy_area: 'cardiovascular',
    us_prevalence: 8500000,
    us_incidence: 500000,
    prevalence_source: 'American Heart Association 2024; CDC PAD estimates',
    diagnosis_rate: 0.50,
    treatment_rate: 0.55,
    cagr_5yr: 6.5,
    major_competitors: [
      'Cilostazol (generic)',
      'Aspirin (generic)',
      'Xarelto (rivaroxaban, Janssen) — vascular dose',
      'Statins (generic)',
      'Endovascular intervention (devices)',
    ],
    market_growth_driver: 'Massive underdiagnosed population, rivaroxaban vascular dose expansion, novel anti-inflammatory approaches, gene therapy for critical limb ischemia',
    therapy_area_pricing_context: 'Generic backbone; novel agents for CLI prevention could command $10K-$25K annually. Large population compensates for moderate pricing.',
  },

  {
    name: 'Hypertrophic Cardiomyopathy',
    synonyms: ['HCM', 'hypertrophic cardiomyopathy', 'HOCM', 'hypertrophic obstructive cardiomyopathy', 'oHCM'],
    icd10_codes: ['I42.1', 'I42.2'],
    therapy_area: 'cardiovascular',
    us_prevalence: 500000,
    us_incidence: 25000,
    prevalence_source: 'HCMA (Hypertrophic Cardiomyopathy Association) 2024; published epidemiology',
    diagnosis_rate: 0.30,
    treatment_rate: 0.60,
    cagr_5yr: 18.0,
    major_competitors: [
      'Camzyos (mavacamten, BMS) — cardiac myosin inhibitor',
      'Beta blockers (generic)',
      'Verapamil (generic)',
      'Disopyramide (generic)',
      'Septal myectomy (surgical)',
    ],
    market_growth_driver: 'Mavacamten as first-in-class cardiac myosin inhibitor, aficamten (Cytokinetics) following, massive underdiagnosis, genetic screening expansion',
    therapy_area_pricing_context: 'Camzyos at $90K annually. Cardiovascular premium for novel mechanism; large undiagnosed population creates growth runway.',
  },

  {
    name: 'Atrial Fibrillation',
    synonyms: ['AFib', 'atrial fibrillation', 'AF', 'paroxysmal AFib', 'persistent AFib', 'permanent AFib'],
    icd10_codes: ['I48.0', 'I48.1', 'I48.2', 'I48.91'],
    therapy_area: 'cardiovascular',
    us_prevalence: 6100000,
    us_incidence: 800000,
    prevalence_source: 'American Heart Association 2024; CDC NHANES; Framingham Heart Study',
    diagnosis_rate: 0.75,
    treatment_rate: 0.80,
    cagr_5yr: 5.5,
    major_competitors: [
      'Eliquis (apixaban, BMS/Pfizer) — DOAC',
      'Xarelto (rivaroxaban, Janssen) — DOAC',
      'Amiodarone (generic)',
      'Flecainide (generic)',
      'Multaq (dronedarone, Sanofi)',
      'Catheter ablation (devices)',
    ],
    market_growth_driver: 'DOAC patent cliffs creating room for novel anticoagulants, Factor XIa inhibitors for safer anticoagulation, rhythm control resurgence, digital health screening',
    therapy_area_pricing_context: 'DOACs at $5K-$6K annually; generic apixaban expected 2026+. Novel anticoagulants (FXIa) need safety advantage for premium pricing.',
  },

  {
    name: 'Deep Vein Thrombosis',
    synonyms: ['DVT', 'deep vein thrombosis', 'venous thromboembolism', 'VTE', 'pulmonary embolism', 'PE'],
    icd10_codes: ['I82.40', 'I82.41', 'I82.42', 'I82.49', 'I26.0', 'I26.9'],
    therapy_area: 'cardiovascular',
    us_prevalence: 900000,
    us_incidence: 600000,
    prevalence_source: 'CDC VTE estimates 2024; ISTH; American Venous Forum',
    diagnosis_rate: 0.80,
    treatment_rate: 0.90,
    cagr_5yr: 4.5,
    major_competitors: [
      'Eliquis (apixaban, BMS/Pfizer)',
      'Xarelto (rivaroxaban, Janssen)',
      'Enoxaparin (generic LMWH)',
      'Warfarin (generic)',
      'Heparin (generic)',
    ],
    market_growth_driver: 'Factor XIa inhibitors for safer anticoagulation (abelacimab, milvexian), extended VTE prophylaxis, cancer-associated VTE treatment optimization',
    therapy_area_pricing_context: 'DOAC-dominated market at $5K-$6K annually; generics impending. FXIa inhibitors need bleeding safety advantage for premium.',
  },

  {
    name: 'Dilated Cardiomyopathy',
    synonyms: ['DCM', 'dilated cardiomyopathy', 'idiopathic DCM', 'familial DCM', 'non-ischemic cardiomyopathy'],
    icd10_codes: ['I42.0'],
    therapy_area: 'cardiovascular',
    us_prevalence: 250000,
    us_incidence: 36000,
    prevalence_source: 'American Heart Association 2024; Cardiomyopathy Foundation; published epidemiology',
    diagnosis_rate: 0.70,
    treatment_rate: 0.75,
    cagr_5yr: 8.0,
    major_competitors: [
      'Standard HF therapies (ACEi/ARB, beta-blockers, MRA, SGLT2i)',
      'Entresto (sacubitril/valsartan, Novartis)',
      'ICD/CRT devices',
      'LVAD (destination therapy)',
    ],
    market_growth_driver: 'Genetic subtype-specific therapies, gene therapy for LMNA and TTN mutations, novel myotropes, precision cardiology approach',
    therapy_area_pricing_context: 'Standard HF therapy backbone; genotype-specific gene therapy could command $500K-$2M one-time. Growing genetic testing adoption.',
  },

  // ──────────────────────────────────────────
  // METABOLIC
  // ──────────────────────────────────────────
  {
    name: 'Type 2 Diabetes',
    synonyms: ['T2DM', 'type 2 diabetes mellitus', 'T2D', 'diabetes', 'adult-onset diabetes'],
    icd10_codes: ['E11', 'E11.0', 'E11.9', 'E11.65'],
    therapy_area: 'cardiovascular',
    us_prevalence: 38000000,
    us_incidence: 1900000,
    prevalence_source: 'CDC National Diabetes Statistics Report 2024; ADA',
    diagnosis_rate: 0.79,        // ~21% undiagnosed per CDC
    treatment_rate: 0.82,
    cagr_5yr: 7.5,
    major_competitors: [
      'Ozempic (semaglutide, Novo Nordisk)',
      'Mounjaro (tirzepatide, Eli Lilly)',
      'Jardiance (empagliflozin, Boehringer)',
      'Farxiga (dapagliflozin, AstraZeneca)',
      'Metformin (generic)',
      'GLP-1 class broadly',
    ],
    market_growth_driver: 'GLP-1 class expansion, NASH comorbidity treatment, weight management, combination approaches, oral GLP-1 development',
    therapy_area_pricing_context: 'GLP-1 agents at $10K-$15K annually; high formulary competition and rebating. Access/adherence critical.',
  },

  {
    name: 'Obesity',
    synonyms: ['obesity', 'overweight and obesity', 'BMI > 30', 'adiposity', 'weight management'],
    icd10_codes: ['E66', 'E66.01', 'E66.09'],
    therapy_area: 'cardiovascular',
    us_prevalence: 108000000,
    us_incidence: 8000000,
    prevalence_source: 'CDC NHANES 2024; Trust for America\'s Health',
    diagnosis_rate: 0.60,        // Many obese patients not coded/treated for obesity
    treatment_rate: 0.25,        // Only fraction receiving pharmacotherapy
    cagr_5yr: 32.0,              // Explosive growth driven by GLP-1 class
    major_competitors: [
      'Wegovy (semaglutide 2.4mg, Novo Nordisk)',
      'Zepbound (tirzepatide, Eli Lilly)',
      'Saxenda (liraglutide, Novo Nordisk)',
      'Qsymia (phentermine/topiramate, Vivus)',
      'Contrave (naltrexone/bupropion, Currax)',
    ],
    market_growth_driver: 'Massive untreated population, next-gen triple agonists (GIP/GLP-1/glucagon), oral formulations, combination approaches, subcutaneous monthly dosing',
    therapy_area_pricing_context: 'Wegovy at $1,350/month ($16K/year). Payer coverage inconsistent but improving. Next-gen differentiation needs to justify premium.',
  },

  {
    name: 'Gout',
    synonyms: ['gout', 'gouty arthritis', 'chronic gout', 'tophaceous gout', 'uncontrolled gout'],
    icd10_codes: ['M10.00', 'M10.01', 'M10.02', 'M10.09', 'M10.9'],
    therapy_area: 'metabolic',
    us_prevalence: 9200000,
    us_incidence: 1000000,
    prevalence_source: 'CDC NHANES 2024; American College of Rheumatology',
    diagnosis_rate: 0.80,
    treatment_rate: 0.50,
    cagr_5yr: 7.5,
    major_competitors: [
      'Allopurinol (generic) — xanthine oxidase inhibitor',
      'Uloric (febuxostat, Takeda) — xanthine oxidase inhibitor',
      'Krystexxa (pegloticase, Horizon/Amgen) — for uncontrolled gout',
      'Colchicine (generic)',
      'Duzallo (lesinurad + allopurinol, Ironwood)',
    ],
    market_growth_driver: 'Krystexxa + immunomodulator combination improving response, novel URAT1 inhibitors, anti-IL-1 for flare prevention, massive undertreated population',
    therapy_area_pricing_context: 'Generic first-line $200-$500/year; Krystexxa at $300K+ annually for refractory disease. Segmented market.',
  },

  {
    name: 'Hyperuricemia',
    synonyms: ['hyperuricemia', 'elevated uric acid', 'asymptomatic hyperuricemia', 'urate crystal disease'],
    icd10_codes: ['E79.0'],
    therapy_area: 'metabolic',
    us_prevalence: 43000000,
    us_incidence: 5000000,
    prevalence_source: 'CDC NHANES 2024; published epidemiology',
    diagnosis_rate: 0.40,
    treatment_rate: 0.20,
    cagr_5yr: 6.0,
    major_competitors: [
      'Allopurinol (generic)',
      'Febuxostat (generic)',
      'Probenecid (generic)',
    ],
    market_growth_driver: 'Emerging link between uric acid and CV/renal outcomes, preventive treatment debate, novel selective URAT1 inhibitors in development',
    therapy_area_pricing_context: 'Generic-dominated landscape; novel agents would need CV/renal outcome data to justify premium pricing at $5K-$15K annually.',
  },

  {
    name: 'Type 1 Diabetes',
    synonyms: ['T1D', 'type 1 diabetes', 'T1DM', 'juvenile diabetes', 'insulin-dependent diabetes'],
    icd10_codes: ['E10', 'E10.0', 'E10.9', 'E10.65'],
    therapy_area: 'metabolic',
    us_prevalence: 2000000,
    us_incidence: 64000,
    prevalence_source: 'JDRF 2024; CDC National Diabetes Statistics; T1D Exchange',
    diagnosis_rate: 0.95,
    treatment_rate: 0.95,
    cagr_5yr: 9.0,
    major_competitors: [
      'Tzield (teplizumab, Provention Bio/Sanofi) — anti-CD3 delay of T1D onset',
      'Insulin analogs (Eli Lilly, Novo Nordisk, Sanofi)',
      'Automated insulin delivery systems (Medtronic, Tandem, Insulet)',
      'CGM devices (Dexcom, Abbott FreeStyle Libre)',
    ],
    market_growth_driver: 'Teplizumab disease delay precedent, beta cell replacement therapies, islet cell transplantation, encapsulated stem cell-derived islets, immunotherapy prevention',
    therapy_area_pricing_context: 'Tzield at $194K one-time for disease delay; insulin $200-$600/month. Beta cell replacement therapies could command $200K-$500K.',
  },

  {
    name: 'Hyperlipidemia',
    synonyms: ['hyperlipidemia', 'dyslipidemia', 'high cholesterol', 'mixed hyperlipidemia', 'hypercholesterolemia'],
    icd10_codes: ['E78.0', 'E78.1', 'E78.2', 'E78.4', 'E78.5'],
    therapy_area: 'metabolic',
    us_prevalence: 94000000,
    us_incidence: 5000000,
    prevalence_source: 'CDC NHANES 2024; American Heart Association; Million Hearts',
    diagnosis_rate: 0.55,
    treatment_rate: 0.50,
    cagr_5yr: 5.0,
    major_competitors: [
      'Statins (atorvastatin, rosuvastatin — generic)',
      'Ezetimibe (generic)',
      'Repatha (evolocumab, Amgen) — PCSK9 mAb',
      'Praluent (alirocumab, Regeneron/Sanofi) — PCSK9 mAb',
      'Leqvio (inclisiran, Novartis) — PCSK9 siRNA',
      'Nexletol (bempedoic acid, Esperion) — ACL inhibitor',
    ],
    market_growth_driver: 'PCSK9 siRNA expansion, Lp(a)-targeting therapies (pelacarsen, olpasiran), ANGPTL3 inhibitors, statin intolerance population, residual CV risk',
    therapy_area_pricing_context: 'Generic statins at $100-$500/year; PCSK9 agents at $5K-$6K/year. Novel Lp(a) therapies could command $5K-$15K annually.',
  },

  // ──────────────────────────────────────────
  // INFECTIOUS DISEASE
  // ──────────────────────────────────────────
  {
    name: 'HIV/AIDS',
    synonyms: ['HIV', 'human immunodeficiency virus', 'AIDS', 'HIV infection', 'HIV-1'],
    icd10_codes: ['B20', 'Z21'],
    therapy_area: 'infectious_disease',
    us_prevalence: 1200000,
    us_incidence: 36000,
    prevalence_source: 'CDC HIV Surveillance Report 2024; HRSA Ryan White',
    diagnosis_rate: 0.87,
    treatment_rate: 0.80,
    cagr_5yr: 4.2,
    major_competitors: [
      'Biktarvy (BIC/TAF/FTC, Gilead)',
      'Dovato (DTG/3TC, ViiV)',
      'Cabenuva (CAB + RPV, ViiV/Janssen) — long-acting IM',
      'Sunlenca (lenacapavir, Gilead) — twice-yearly SC',
      'Descovy (TAF/FTC, Gilead)',
    ],
    market_growth_driver: 'Ultra-long-acting formulations (implant/annual), cure strategies, broadly neutralizing antibodies, prevention expansion',
    therapy_area_pricing_context: 'Established regimens $20K-$40K annually. Long-acting innovations command premium for convenience; cure would be high single-payment scenario',
  },

  {
    name: 'Respiratory Syncytial Virus',
    synonyms: ['RSV', 'respiratory syncytial virus', 'RSV infection', 'RSV bronchiolitis', 'RSV pneumonia'],
    icd10_codes: ['J12.1', 'J20.5', 'J21.0'],
    therapy_area: 'infectious_disease',
    us_prevalence: 2000000,
    us_incidence: 6000000,
    prevalence_source: 'CDC RSV Surveillance 2024; NREVSS',
    diagnosis_rate: 0.60,
    treatment_rate: 0.50,
    cagr_5yr: 25.0,
    major_competitors: [
      'Beyfortus (nirsevimab, AstraZeneca/Sanofi) — long-acting RSV mAb prevention',
      'Synagis (palivizumab, AstraZeneca) — RSV mAb prevention (high-risk infants)',
      'Arexvy (RSV vaccine, GSK) — older adults',
      'Abrysvo (RSV vaccine, Pfizer) — maternal/older adults',
      'mResvia (RSV mRNA vaccine, Moderna) — older adults',
    ],
    market_growth_driver: 'First-ever RSV vaccines approved 2023, infant immunization via maternal vaccination, long-acting mAb replacing monthly palivizumab, adult RSV treatment gap',
    therapy_area_pricing_context: 'Beyfortus at $495/dose; RSV vaccines at $180-$295. Combined infant+elderly market projected at $10B+ globally.',
  },

  {
    name: 'Influenza',
    synonyms: ['flu', 'influenza', 'influenza A', 'influenza B', 'seasonal influenza', 'pandemic influenza'],
    icd10_codes: ['J09', 'J10', 'J11'],
    therapy_area: 'infectious_disease',
    us_prevalence: 30000000,
    us_incidence: 30000000,
    prevalence_source: 'CDC FluView 2024; seasonal estimates',
    diagnosis_rate: 0.40,
    treatment_rate: 0.30,
    cagr_5yr: 8.0,
    major_competitors: [
      'Tamiflu (oseltamivir, generic) — neuraminidase inhibitor',
      'Xofluza (baloxavir marboxil, Roche) — cap-dependent endonuclease inhibitor',
      'Rapivab (peramivir, BioCryst) — IV neuraminidase inhibitor',
      'Influenza vaccines (multiple manufacturers)',
    ],
    market_growth_driver: 'mRNA influenza vaccine development, universal influenza vaccine, combination flu/COVID vaccines, novel antivirals for hospitalized patients, pandemic preparedness',
    therapy_area_pricing_context: 'Seasonal vaccines $25-$75/dose; Xofluza at $150/course. Universal vaccine could be premium. Massive seasonal volume.',
  },

  {
    name: 'MRSA Infections',
    synonyms: ['MRSA', 'methicillin-resistant Staphylococcus aureus', 'staph aureus infection', 'serious bacterial infection', 'SBI'],
    icd10_codes: ['A49.02', 'B95.62'],
    therapy_area: 'infectious_disease',
    us_prevalence: 120000,
    us_incidence: 80000,
    prevalence_source: 'CDC AR Threats Report 2024; NHSN HAI data',
    diagnosis_rate: 0.90,
    treatment_rate: 0.95,
    cagr_5yr: 5.0,
    major_competitors: [
      'Vancomycin (generic)',
      'Daptomycin (generic)',
      'Linezolid (generic)',
      'Zevtera (ceftobiprole, Basilea)',
      'Dalbavancin (generic)',
      'Telavancin (generic)',
    ],
    market_growth_driver: 'Rising antimicrobial resistance, GAIN Act incentives, LPAD pathway for limited populations, novel bactericidal mechanisms, anti-virulence approaches',
    therapy_area_pricing_context: 'Generic antibiotics create severe pricing pressure; novel agents $5K-$15K per treatment course. Market access challenged by short treatment duration.',
  },

  {
    name: 'Clostridioides difficile Infection',
    synonyms: ['C. diff', 'CDI', 'C. difficile', 'Clostridioides difficile', 'pseudomembranous colitis', 'CDAD'],
    icd10_codes: ['A04.71', 'A04.72'],
    therapy_area: 'infectious_disease',
    us_prevalence: 500000,
    us_incidence: 500000,
    prevalence_source: 'CDC HAI/AR data 2024; published surveillance estimates',
    diagnosis_rate: 0.85,
    treatment_rate: 0.90,
    cagr_5yr: 8.5,
    major_competitors: [
      'Vancomycin oral (generic)',
      'Fidaxomicin (Dificid, Merck)',
      'Vowst (fecal microbiota spores, Seres Therapeutics) — oral microbiome therapy',
      'Rebyota (fecal microbiota, Ferring) — rectal microbiome therapy',
      'Bezlotoxumab (Zinplava, Merck) — anti-toxin B mAb',
    ],
    market_growth_driver: 'Microbiome-based prevention of recurrence, engineered probiotics, anti-toxin approaches, narrow-spectrum antibiotics, recurrence prevention focus',
    therapy_area_pricing_context: 'Fidaxomicin at $4K/course; microbiome therapies $17K-$18K per course. Recurrence prevention valued by payers and systems.',
  },

  {
    name: 'Hepatitis B',
    synonyms: ['HBV', 'hepatitis B', 'chronic hepatitis B', 'CHB', 'HBV infection'],
    icd10_codes: ['B18.0', 'B18.1', 'B16'],
    therapy_area: 'infectious_disease',
    us_prevalence: 2400000,
    us_incidence: 15000,
    prevalence_source: 'CDC Hepatitis Surveillance 2024; HBF; published estimates',
    diagnosis_rate: 0.35,
    treatment_rate: 0.25,
    cagr_5yr: 10.0,
    major_competitors: [
      'Tenofovir alafenamide (Vemlidy, Gilead)',
      'Tenofovir disoproxil (generic)',
      'Entecavir (generic)',
      'Pegylated interferon (generic)',
      'Hepcludex (bulevirtide, Gilead) — entry inhibitor (EU approved)',
    ],
    market_growth_driver: 'Functional cure pursuit (HBsAg loss), RNAi therapies (JNJ-3989, VIR-2218), ASO approaches, combination cure strategies, massive underdiagnosed population',
    therapy_area_pricing_context: 'Chronic NUC therapy at $2K-$20K annually; functional cure therapy could command $50K-$100K+ given curative intent.',
  },

  // ──────────────────────────────────────────
  // HEMATOLOGY (NON-ONCOLOGY)
  // ──────────────────────────────────────────
  {
    name: 'Sickle Cell Disease',
    synonyms: ['SCD', 'sickle cell anemia', 'HbSS disease', 'hemoglobin SS', 'sickle cell'],
    icd10_codes: ['D57.0', 'D57.1', 'D57.2', 'D57.3', 'D57.4', 'D57.8'],
    therapy_area: 'rare_disease',
    us_prevalence: 100000,
    us_incidence: 2000,
    prevalence_source: 'CDC Sickle Cell Disease Data; ASH 2024',
    diagnosis_rate: 0.98,        // Universal newborn screening
    treatment_rate: 0.75,
    cagr_5yr: 25.0,
    major_competitors: [
      'Casgevy (exagamglogene, Vertex/CRISPR) — gene editing cure',
      'Lyfgenia (lovotibeglogene, bluebird bio) — gene therapy',
      'Oxbryta (voxelotor, Pfizer) — recently withdrawn',
      'Adakveo (crizanlizumab, Novartis) — withdrawn',
      'Endari (L-glutamine, Emmaus)',
      'Hydroxyurea (generic)',
    ],
    market_growth_driver: 'Gene therapy/editing expansion, anti-sickling agents, VOC prevention, pediatric approaches',
    therapy_area_pricing_context: 'Gene therapies at $2-3M+ for cure; chronic therapies $50K-$150K. Access disparities given predominantly Black patient population.',
  },

  {
    name: 'Iron Deficiency Anemia',
    synonyms: ['IDA', 'iron deficiency anemia', 'iron deficiency', 'anemia of iron deficiency'],
    icd10_codes: ['D50.0', 'D50.1', 'D50.8', 'D50.9'],
    therapy_area: 'hematology',
    us_prevalence: 5000000,
    us_incidence: 2000000,
    prevalence_source: 'CDC NHANES 2024; American Society of Hematology',
    diagnosis_rate: 0.65,
    treatment_rate: 0.60,
    cagr_5yr: 7.0,
    major_competitors: [
      'Injectafer (ferric carboxymaltose, American Regent)',
      'Feraheme (ferumoxytol, AMAG Pharma)',
      'Monoferric (ferric derisomaltose, Pharmacosmos)',
      'Iron sucrose (generic)',
      'Oral iron supplements (generic)',
    ],
    market_growth_driver: 'IV iron formulations with fewer infusions, CKD-associated anemia overlap, HIF-PHI oral agents, IBD/GI-associated IDA growing population',
    therapy_area_pricing_context: 'IV iron $500-$3K per infusion course; oral iron $50-$200/year. Hospital infusion economics drive product differentiation.',
  },

  {
    name: 'Immune Thrombocytopenia',
    synonyms: ['ITP', 'immune thrombocytopenic purpura', 'idiopathic thrombocytopenic purpura', 'autoimmune thrombocytopenia'],
    icd10_codes: ['D69.3'],
    therapy_area: 'hematology',
    us_prevalence: 60000,
    us_incidence: 12000,
    prevalence_source: 'Platelet Disorder Support Association 2024; published epidemiology',
    diagnosis_rate: 0.80,
    treatment_rate: 0.75,
    cagr_5yr: 9.0,
    major_competitors: [
      'Promacta (eltrombopag, Novartis) — TPO receptor agonist',
      'Nplate (romiplostim, Amgen) — TPO receptor agonist',
      'Doptelet (avatrombopag, Sobi)',
      'Tavlesse (fostamatinib, Rigel) — SYK inhibitor',
      'Rituximab (off-label)',
      'IVIg (various)',
      'Corticosteroids (generic)',
    ],
    market_growth_driver: 'FcRn inhibitor development, Bruton TKI approaches, neonatal Fc receptor blockade, combination strategies for refractory ITP',
    therapy_area_pricing_context: 'TPO receptor agonists at $50K-$100K annually; FcRn inhibitors could command $200K+. Chronic relapsing disease supports sustained therapy.',
  },

  {
    name: 'Thrombotic Thrombocytopenic Purpura',
    synonyms: ['TTP', 'thrombotic thrombocytopenic purpura', 'acquired TTP', 'aTTP', 'ADAMTS13 deficiency'],
    icd10_codes: ['M31.1'],
    therapy_area: 'hematology',
    us_prevalence: 4000,
    us_incidence: 1500,
    prevalence_source: 'Published epidemiology 2024; TTP Foundation; registry data',
    diagnosis_rate: 0.85,
    treatment_rate: 0.95,
    cagr_5yr: 10.0,
    major_competitors: [
      'Cablivi (caplacizumab, Sanofi) — anti-vWF nanobody',
      'Plasma exchange (standard of care)',
      'Corticosteroids (generic)',
      'Rituximab (off-label)',
    ],
    market_growth_driver: 'Caplacizumab adoption in acute episodes, recombinant ADAMTS13 replacement therapy, prevention of relapse strategies, improved diagnosis speed',
    therapy_area_pricing_context: 'Cablivi at $270K per acute treatment course; rare hematologic emergency supports premium pricing. Orphan designation.',
  },

  {
    name: 'Paroxysmal Nocturnal Hemoglobinuria',
    synonyms: ['PNH', 'paroxysmal nocturnal hemoglobinuria', 'Marchiafava-Micheli syndrome'],
    icd10_codes: ['D59.5'],
    therapy_area: 'hematology',
    us_prevalence: 5000,
    us_incidence: 400,
    prevalence_source: 'AAMDS International Foundation 2024; published epidemiology',
    diagnosis_rate: 0.70,
    treatment_rate: 0.85,
    cagr_5yr: 8.0,
    major_competitors: [
      'Soliris (eculizumab, Alexion) — complement C5 inhibitor',
      'Ultomiris (ravulizumab, Alexion) — long-acting C5 inhibitor',
      'Empaveli (pegcetacoplan, Apellis) — C3 inhibitor',
      'Iptacopan (Novartis) — Factor B inhibitor oral',
      'Voydeya (danicopan, Alexion) — Factor D inhibitor oral add-on',
    ],
    market_growth_driver: 'Oral complement inhibitors disrupting IV infusion paradigm, proximal complement blockade (C3/Factor B), combination strategies, Soliris biosimilar pressure',
    therapy_area_pricing_context: 'Soliris/Ultomiris at $400K-$500K annually; oral alternatives may be priced at $200K-$350K. Ultra-rare with orphan exclusivity.',
  },

  {
    name: 'Beta-Thalassemia',
    synonyms: ['beta-thalassemia', 'thalassemia major', 'thalassemia intermedia', 'transfusion-dependent thalassemia', 'TDT'],
    icd10_codes: ['D56.1', 'D56.2', 'D56.3', 'D56.9'],
    therapy_area: 'hematology',
    us_prevalence: 15000,
    us_incidence: 500,
    prevalence_source: 'Cooley Anemia Foundation 2024; Thalassemia International Federation',
    diagnosis_rate: 0.95,
    treatment_rate: 0.90,
    cagr_5yr: 18.0,
    major_competitors: [
      'Casgevy (exagamglogene, Vertex/CRISPR) — gene editing cure',
      'Zynteglo (betibeglogene autotemcel, bluebird bio) — gene therapy',
      'Reblozyl (luspatercept, BMS) — erythroid maturation agent',
      'Deferasirox (generic) — iron chelation',
      'Chronic transfusion therapy',
    ],
    market_growth_driver: 'Gene therapy/editing curative approaches, luspatercept reducing transfusion burden, novel gene therapy with improved vectors, global expansion opportunity',
    therapy_area_pricing_context: 'Casgevy at $2.2M one-time; Zynteglo at $2.8M; Reblozyl at $150K annually. Curative gene therapies command premium vs lifetime transfusion costs.',
  },

  // ──────────────────────────────────────────
  // OPHTHALMOLOGY
  // ──────────────────────────────────────────
  {
    name: 'Neovascular Age-Related Macular Degeneration',
    synonyms: ['wet AMD', 'nAMD', 'neovascular AMD', 'exudative AMD', 'wet macular degeneration'],
    icd10_codes: ['H35.31', 'H35.32'],
    therapy_area: 'ophthalmology',
    us_prevalence: 1800000,
    us_incidence: 200000,
    prevalence_source: 'Bright Focus Foundation 2024; AAO',
    diagnosis_rate: 0.85,
    treatment_rate: 0.70,
    cagr_5yr: 7.8,
    major_competitors: [
      'Eylea (aflibercept, Regeneron)',
      'Eylea HD (high-dose aflibercept, Regeneron)',
      'Vabysmo (faricimab, Roche) — anti-VEGF + Ang-2',
      'Susvimo (ranibizumab port delivery, Roche)',
      'Syfovre (pegcetacoplan, Apellis)',
      'Lucentis (ranibizumab, Genentech)',
    ],
    market_growth_driver: 'Extended dosing intervals, gene therapy single-dose cure potential, combination anti-VEGF approaches, GA prevention',
    therapy_area_pricing_context: 'Anti-VEGF injections $2K-$8K per dose; $15K-$40K annually. Gene therapy for sustained delivery could be high-value single-payment.',
  },

  {
    name: 'Diabetic Macular Edema',
    synonyms: ['DME', 'diabetic macular edema', 'diabetic macular oedema', 'DMO', 'center-involving DME', 'CI-DME'],
    icd10_codes: ['E11.311', 'E11.3211', 'E11.3311', 'E11.3411', 'E11.3511'],
    therapy_area: 'ophthalmology',
    us_prevalence: 750000,
    us_incidence: 100000,
    prevalence_source: 'National Eye Institute 2024; AAO; published prevalence estimates',
    diagnosis_rate: 0.70,
    treatment_rate: 0.60,
    cagr_5yr: 8.5,
    major_competitors: [
      'Eylea (aflibercept, Regeneron)',
      'Eylea HD (high-dose aflibercept, Regeneron)',
      'Vabysmo (faricimab, Roche) — anti-VEGF + Ang-2',
      'Lucentis (ranibizumab, Genentech)',
      'Ozurdex (dexamethasone implant, AbbVie)',
      'Iluvien (fluocinolone acetonide implant, Alimera)',
    ],
    market_growth_driver: 'Extended dosing intervals reducing treatment burden, bispecific anti-VEGF/Ang-2, port delivery systems, gene therapy for sustained expression',
    therapy_area_pricing_context: 'Anti-VEGF injections $1.8K-$8K per dose; steroid implants $1K-$2K. Chronic disease with high treatment frequency drives annual costs to $15K-$40K.',
  },

  {
    name: 'Geographic Atrophy',
    synonyms: ['GA', 'geographic atrophy', 'dry AMD', 'advanced dry AMD', 'atrophic AMD'],
    icd10_codes: ['H35.31', 'H35.3110', 'H35.3120'],
    therapy_area: 'ophthalmology',
    us_prevalence: 1000000,
    us_incidence: 150000,
    prevalence_source: 'Bright Focus Foundation 2024; AAO; BrightFocus GA estimates',
    diagnosis_rate: 0.75,
    treatment_rate: 0.25,
    cagr_5yr: 30.0,
    major_competitors: [
      'Syfovre (pegcetacoplan, Apellis) — complement C3 inhibitor, first FDA-approved for GA',
      'Izervay (avacincaptad pegol, Iveric Bio/Astellas) — complement C5 inhibitor',
    ],
    market_growth_driver: 'First-ever FDA approvals in 2023, massive untreated prevalent pool, monthly IVT injection burden driving extended-dosing innovation, gene therapy approaches',
    therapy_area_pricing_context: 'Syfovre at $2.2K per injection ($26K-$58K annually depending on frequency); Izervay similar. New market category with major growth potential.',
  },

  {
    name: 'Glaucoma',
    synonyms: ['glaucoma', 'open-angle glaucoma', 'POAG', 'primary open-angle glaucoma', 'angle-closure glaucoma', 'ocular hypertension'],
    icd10_codes: ['H40.10', 'H40.11', 'H40.12', 'H40.13', 'H40.20', 'H40.9'],
    therapy_area: 'ophthalmology',
    us_prevalence: 3000000,
    us_incidence: 300000,
    prevalence_source: 'Glaucoma Research Foundation 2024; NEI; AAO epidemiology',
    diagnosis_rate: 0.50,
    treatment_rate: 0.70,
    cagr_5yr: 5.5,
    major_competitors: [
      'Latanoprost (generic) — prostaglandin analog',
      'Timolol (generic) — beta blocker',
      'Vyzulta (latanoprostene bunod, Bausch + Lomb) — NO-donating prostaglandin',
      'Rhopressa (netarsudil, Aerie/Alcon) — Rho kinase inhibitor',
      'Rocklatan (netarsudil/latanoprost, Aerie/Alcon) — fixed combination',
      'Durysta (bimatoprost implant, AbbVie) — sustained release',
      'iStent (Glaukos) — MIGS device',
    ],
    market_growth_driver: 'Sustained-release drug delivery reducing adherence burden, MIGS procedures growth, Rho kinase class expansion, gene therapy for neuroprotection',
    therapy_area_pricing_context: 'Generic drops at $50-$300/year; branded drops $2K-$4K/year; MIGS devices $1K-$3K. Sustained-release implants $500-$1K per implant.',
  },

  {
    name: 'Retinitis Pigmentosa',
    synonyms: ['RP', 'retinitis pigmentosa', 'rod-cone dystrophy', 'hereditary retinal dystrophy'],
    icd10_codes: ['H35.52'],
    therapy_area: 'ophthalmology',
    us_prevalence: 100000,
    us_incidence: 3000,
    prevalence_source: 'Foundation Fighting Blindness 2024; published epidemiology',
    diagnosis_rate: 0.80,
    treatment_rate: 0.25,
    cagr_5yr: 20.0,
    major_competitors: [
      'Luxturna (voretigene neparvovec, Spark/Roche) — RPE65 gene therapy only',
      'Vitamin A palmitate (supplement)',
      'No broadly applicable approved therapies',
    ],
    market_growth_driver: 'Luxturna gene therapy precedent for RPE65, optogenetics approaches, CRISPR gene editing, neuroprotective agents, broad genetic heterogeneity creates multiple targets',
    therapy_area_pricing_context: 'Luxturna at $850K per eye ($1.7M total). Ultra-rare; gene therapy pricing for inherited retinal diseases established at premium.',
  },

  // ──────────────────────────────────────────
  // PULMONOLOGY / RESPIRATORY
  // ──────────────────────────────────────────
  {
    name: 'Idiopathic Pulmonary Fibrosis',
    synonyms: ['IPF', 'idiopathic pulmonary fibrosis', 'pulmonary fibrosis', 'cryptogenic fibrosing alveolitis'],
    icd10_codes: ['J84.112'],
    therapy_area: 'pulmonology',
    us_prevalence: 130000,
    us_incidence: 50000,
    prevalence_source: 'Pulmonary Fibrosis Foundation 2024; published epidemiology estimates',
    diagnosis_rate: 0.50,
    treatment_rate: 0.65,
    cagr_5yr: 9.0,
    major_competitors: [
      'Ofev (nintedanib, Boehringer Ingelheim) — anti-fibrotic',
      'Esbriet (pirfenidone, Roche) — anti-fibrotic',
    ],
    market_growth_driver: 'Combination anti-fibrotic approaches, inhaled delivery, novel targets (autotaxin, integrin, LPAR1), progressive fibrosing ILD expansion',
    therapy_area_pricing_context: 'Anti-fibrotics at $100K+ annually. Two-drug market with room for combination and improved efficacy agents.',
  },

  {
    name: 'Severe Asthma',
    synonyms: ['severe asthma', 'uncontrolled asthma', 'eosinophilic asthma', 'type 2 severe asthma', 'biologic-eligible asthma'],
    icd10_codes: ['J45.50', 'J45.51', 'J45.52'],
    therapy_area: 'pulmonology',
    us_prevalence: 2400000,
    us_incidence: 300000,
    prevalence_source: 'Asthma and Allergy Foundation 2024; CDC NHIS estimates (severe subset ~8% of 25M total)',
    diagnosis_rate: 0.80,
    treatment_rate: 0.50,
    cagr_5yr: 10.0,
    major_competitors: [
      'Dupixent (dupilumab, Sanofi/Regeneron) — anti-IL-4Ra',
      'Fasenra (benralizumab, AstraZeneca) — anti-IL-5R',
      'Nucala (mepolizumab, GSK) — anti-IL-5',
      'Cinqair (reslizumab, Teva) — anti-IL-5',
      'Xolair (omalizumab, Roche) — anti-IgE',
      'Tezspire (tezepelumab, AstraZeneca/Amgen) — anti-TSLP',
    ],
    market_growth_driver: 'Dupixent broad type 2 dominance, TSLP pathway for non-eosinophilic asthma, oral biologics, biologic combination strategies, alarmins targeting',
    therapy_area_pricing_context: 'Biologics at $30K-$40K annually. Large biologic-eligible population with <50% penetration creates growth runway.',
  },

  {
    name: 'Chronic Obstructive Pulmonary Disease',
    synonyms: ['COPD', 'chronic obstructive pulmonary disease', 'emphysema', 'chronic bronchitis'],
    icd10_codes: ['J44.0', 'J44.1', 'J44.9', 'J43.9'],
    therapy_area: 'pulmonology',
    us_prevalence: 16000000,
    us_incidence: 800000,
    prevalence_source: 'CDC NHIS 2024; GOLD Report; American Lung Association',
    diagnosis_rate: 0.60,
    treatment_rate: 0.70,
    cagr_5yr: 6.5,
    major_competitors: [
      'Trelegy Ellipta (FF/UMEC/VI, GSK) — triple inhaler',
      'Breztri Aerosphere (BGF MDI, AstraZeneca) — triple inhaler',
      'Dupixent (dupilumab, Sanofi/Regeneron) — anti-IL-4Ra (T2 COPD)',
      'Spiriva (tiotropium, Boehringer)',
      'Symbicort (budesonide/formoterol, AstraZeneca)',
      'Advair (fluticasone/salmeterol, GSK)',
    ],
    market_growth_driver: 'Dupixent approval for eosinophilic COPD (type 2 inflammation), anti-IL-33 approaches, triple therapy optimization, COPD exacerbation prevention biologics',
    therapy_area_pricing_context: 'Triple inhalers at $6K-$8K annually; biologics for COPD at $36K+ annually. Massive addressable population for biologic upgrade.',
  },

  {
    name: 'Bronchiectasis',
    synonyms: ['bronchiectasis', 'non-CF bronchiectasis', 'NCFB', 'non-cystic fibrosis bronchiectasis'],
    icd10_codes: ['J47.0', 'J47.1', 'J47.9'],
    therapy_area: 'pulmonology',
    us_prevalence: 500000,
    us_incidence: 50000,
    prevalence_source: 'American Lung Association 2024; published epidemiology estimates',
    diagnosis_rate: 0.45,
    treatment_rate: 0.55,
    cagr_5yr: 12.0,
    major_competitors: [
      'No FDA-approved therapies specifically for non-CF bronchiectasis',
      'Inhaled antibiotics (off-label — tobramycin, aztreonam)',
      'Airway clearance devices',
      'Brensocatib (AstraZeneca) — DPP1 inhibitor, Phase 3',
    ],
    market_growth_driver: 'Complete treatment void, brensocatib neutrophil elastase pathway, CFTR modulators for CFTR-related bronchiectasis, anti-inflammatory approaches',
    therapy_area_pricing_context: 'No approved therapies; first approved agent could command $30K-$80K annually. Growing diagnosed population.',
  },

  // ──────────────────────────────────────────
  // DERMATOLOGY
  // ──────────────────────────────────────────
  {
    name: 'Hidradenitis Suppurativa',
    synonyms: ['HS', 'hidradenitis suppurativa', 'acne inversa', 'HS disease'],
    icd10_codes: ['L73.2'],
    therapy_area: 'immunology',
    us_prevalence: 200000,
    us_incidence: 20000,
    prevalence_source: 'HS Foundation 2024; published epidemiology estimates (often underdiagnosed)',
    diagnosis_rate: 0.40,
    treatment_rate: 0.35,
    cagr_5yr: 18.0,
    major_competitors: [
      'Humira (adalimumab, AbbVie) — first FDA-approved biologic for HS',
      'Cosentyx (secukinumab, Novartis) — anti-IL-17A, recently approved for HS',
      'Bimzelx (bimekizumab, UCB) — anti-IL-17A/F, approved for HS',
      'Antibiotics (generic)',
    ],
    market_growth_driver: 'IL-17 class expansion, complement inhibition, JAK inhibitors, massive underdiagnosis creates large untapped market, multi-cytokine approaches',
    therapy_area_pricing_context: 'Biologics at $60K-$80K annually. Large underdiagnosed population with severe disease burden. New approvals expanding treatment options.',
  },

  {
    name: 'Chronic Spontaneous Urticaria',
    synonyms: ['CSU', 'chronic urticaria', 'chronic spontaneous urticaria', 'chronic idiopathic urticaria', 'CIU'],
    icd10_codes: ['L50.1', 'L50.8', 'L50.9'],
    therapy_area: 'immunology',
    us_prevalence: 1500000,
    us_incidence: 200000,
    prevalence_source: 'Allergy & Asthma Network 2024; published epidemiology estimates',
    diagnosis_rate: 0.60,
    treatment_rate: 0.55,
    cagr_5yr: 12.0,
    major_competitors: [
      'Xolair (omalizumab, Roche) — anti-IgE',
      'Antihistamines (generic, first-line)',
      'Dupixent (dupilumab, Sanofi/Regeneron) — Phase 3 for CSU',
      'Ligelizumab (Novartis) — next-gen anti-IgE (development uncertain)',
    ],
    market_growth_driver: 'Anti-IgE class evolution, Bruton TKI for mast cell targeting, dupilumab expansion, rapid complete response as treatment goal',
    therapy_area_pricing_context: 'Xolair at $30K-$36K annually. Large undertreated population with room for novel mechanisms commanding $40K-$60K.',
  },

  // ──────────────────────────────────────────
  // NEPHROLOGY
  // ──────────────────────────────────────────
  {
    name: 'IgA Nephropathy',
    synonyms: ['IgAN', 'IgA nephropathy', 'Berger disease', "Berger's disease", 'IgA glomerulonephritis'],
    icd10_codes: ['N02.8'],
    therapy_area: 'nephrology',
    us_prevalence: 130000,
    us_incidence: 15000,
    prevalence_source: 'IgA Nephropathy Foundation 2024; published epidemiology estimates',
    diagnosis_rate: 0.50,
    treatment_rate: 0.60,
    cagr_5yr: 25.0,
    major_competitors: [
      'Filspari (sparsentan, Travere) — dual endothelin/angiotensin receptor antagonist',
      'Tarpeyo (budesonide delayed-release, Calliditas) — targeted-release corticosteroid',
      'ACE inhibitors / ARBs (generic)',
      'SGLT2 inhibitors (off-label)',
    ],
    market_growth_driver: 'First dedicated IgAN approvals (2022-2023), complement inhibitors (iptacopan, narsoplimab), APRIL/BAFF targeting, SGLT2 renal protection evidence',
    therapy_area_pricing_context: 'Filspari at $200K annually; Tarpeyo at $55K. Novel mechanisms for IgAN at $100K-$200K. Previously untreatable rare nephrology.',
  },

  {
    name: 'Lupus Nephritis',
    synonyms: ['LN', 'lupus nephritis', 'SLE nephritis', 'lupus kidney disease', 'class III/IV/V LN'],
    icd10_codes: ['M32.14', 'M32.15'],
    therapy_area: 'nephrology',
    us_prevalence: 60000,
    us_incidence: 8000,
    prevalence_source: 'Lupus Foundation of America 2024; published nephritis prevalence in SLE (30-50%)',
    diagnosis_rate: 0.75,
    treatment_rate: 0.80,
    cagr_5yr: 14.0,
    major_competitors: [
      'Lupkynis (voclosporin, Aurinia) — calcineurin inhibitor approved for LN',
      'Benlysta (belimumab, GSK) — anti-BLyS, approved for LN',
      'Mycophenolate (generic)',
      'Cyclophosphamide (generic)',
      'Rituximab (off-label)',
    ],
    market_growth_driver: 'Voclosporin + mycophenolate combination, CD20/CD19 B cell depletion, complement inhibition, obinutuzumab for LN, novel biologic combinations',
    therapy_area_pricing_context: 'Lupkynis at $80K annually; Benlysta at $35K. Combination biologics for severe LN could command $100K+ combined annually.',
  },

  {
    name: 'Focal Segmental Glomerulosclerosis',
    synonyms: ['FSGS', 'focal segmental glomerulosclerosis', 'focal glomerulosclerosis', 'primary FSGS'],
    icd10_codes: ['N04.1'],
    therapy_area: 'nephrology',
    us_prevalence: 40000,
    us_incidence: 7000,
    prevalence_source: 'NephCure Foundation 2024; published epidemiology estimates',
    diagnosis_rate: 0.65,
    treatment_rate: 0.70,
    cagr_5yr: 15.0,
    major_competitors: [
      'Filspari (sparsentan, Travere) — dual endothelin/angiotensin receptor antagonist (approved for IgAN, studying FSGS)',
      'Cyclosporine (generic)',
      'Tacrolimus (generic)',
      'ACE inhibitors / ARBs (generic)',
    ],
    market_growth_driver: 'No approved targeted therapies, APOL1-targeting for genetic FSGS, podocyte biology advances, endothelin receptor antagonism, complement pathway',
    therapy_area_pricing_context: 'No approved therapies; rare glomerular disease with orphan potential. First approved agent could command $100K-$300K annually.',
  },

  // ──────────────────────────────────────────
  // ENDOCRINOLOGY
  // ──────────────────────────────────────────
  {
    name: 'Acromegaly',
    synonyms: ['acromegaly', 'growth hormone excess', 'GH-secreting pituitary adenoma'],
    icd10_codes: ['E22.0'],
    therapy_area: 'rare_disease',
    us_prevalence: 25000,
    us_incidence: 1500,
    prevalence_source: 'Acromegaly Community 2024; published epidemiology estimates',
    diagnosis_rate: 0.60,
    treatment_rate: 0.85,
    cagr_5yr: 7.0,
    major_competitors: [
      'Sandostatin LAR (octreotide, Novartis) — somatostatin analog',
      'Somatuline Depot (lanreotide, Ipsen) — somatostatin analog',
      'Mycapssa (oral octreotide, Chiasma/Amryt)',
      'Somavert (pegvisomant, Pfizer) — GH receptor antagonist',
      'Signifor LAR (pasireotide, Recordati) — multireceptor SSA',
    ],
    market_growth_driver: 'Oral somatostatin analog paradigm shift, next-gen GH receptor antagonists, combination approaches, improved diagnosis via IGF-1 screening',
    therapy_area_pricing_context: 'Somatostatin analogs $30K-$60K annually; Somavert $80K+; Mycapssa oral at $80K+. Chronic rare disease with sustained pricing.',
  },

  {
    name: 'Cushing Syndrome',
    synonyms: ["Cushing's syndrome", "Cushing's disease", 'hypercortisolism', 'ACTH-dependent Cushing'],
    icd10_codes: ['E24.0', 'E24.2', 'E24.8', 'E24.9'],
    therapy_area: 'rare_disease',
    us_prevalence: 15000,
    us_incidence: 1200,
    prevalence_source: 'CSRF (Cushing Support & Research Foundation) 2024; published epidemiology',
    diagnosis_rate: 0.55,
    treatment_rate: 0.80,
    cagr_5yr: 10.0,
    major_competitors: [
      'Isturisa (osilodrostat, Recordati) — 11-beta-hydroxylase inhibitor',
      'Korlym (mifepristone, Corcept) — glucocorticoid receptor antagonist',
      'Recorlev (levoketoconazole, Xeris/Corcept)',
      'Signifor (pasireotide, Recordati) — somatostatin analog',
      'Metyrapone (generic)',
    ],
    market_growth_driver: 'Cortisol receptor antagonist improvements, next-gen steroidogenesis inhibitors, CRF1 antagonists, improved pituitary tumor targeting',
    therapy_area_pricing_context: 'Korlym at $200K+ annually; Isturisa at $120K+. Rare endocrine disease with orphan pricing.',
  },

  {
    name: 'Chronic Kidney Disease',
    synonyms: ['CKD', 'chronic kidney disease', 'chronic renal failure', 'CKD stage 3-5', 'diabetic kidney disease', 'DKD'],
    icd10_codes: ['N18.1', 'N18.2', 'N18.3', 'N18.4', 'N18.5', 'N18.6', 'N18.9'],
    therapy_area: 'nephrology',
    us_prevalence: 37000000,
    us_incidence: 3000000,
    prevalence_source: 'CDC CKD Fact Sheet 2024; USRDS; National Kidney Foundation',
    diagnosis_rate: 0.40,
    treatment_rate: 0.45,
    cagr_5yr: 9.0,
    major_competitors: [
      'Farxiga (dapagliflozin, AstraZeneca) — SGLT2 inhibitor',
      'Jardiance (empagliflozin, Boehringer) — SGLT2 inhibitor',
      'Kerendia (finerenone, Bayer) — non-steroidal MRA',
      'ACE inhibitors / ARBs (generic)',
      'Jesduvroq (daprodustat, GSK) — HIF-PHI for anemia',
    ],
    market_growth_driver: 'SGLT2 class CKD indication expansion, non-steroidal MRA combination, GLP-1 renal protection data, massive underdiagnosed population, CKD progression prevention',
    therapy_area_pricing_context: 'SGLT2 inhibitors at $6K-$8K annually; Kerendia at $6K. Massive patient population means moderate pricing generates very large market.',
  },

];

// Export helper for lookup
export function findIndicationByName(name: string): IndicationData | undefined {
  const normalized = name.toLowerCase().trim();
  return INDICATION_DATA.find(i =>
    i.name.toLowerCase() === normalized ||
    i.synonyms.some(s => s.toLowerCase() === normalized) ||
    normalized.includes(i.name.toLowerCase()) ||
    i.name.toLowerCase().includes(normalized)
  );
}

export function getIndicationNames(): string[] {
  return INDICATION_DATA.map(i => i.name);
}

export function getIndicationSuggestions(query: string): IndicationData[] {
  if (!query || query.length < 2) return INDICATION_DATA.slice(0, 10);
  const q = query.toLowerCase();
  return INDICATION_DATA.filter(i =>
    i.name.toLowerCase().includes(q) ||
    i.synonyms.some(s => s.toLowerCase().includes(q))
  ).slice(0, 10);
}
